Multiplex repression of immunosuppressive genes

The CRISPR-based gene silencing system targets immunosuppressive genes in immune and tumor cells to enhance anti-tumor immune response, addressing the limitations of current checkpoint blockade immunotherapy by increasing CD8+ T cell infiltration and improving cancer treatment efficacy.

CN119095627APending Publication Date: 2024-12-06YALE UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035239.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-22
Filing Date
2023-02-17
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current checkpoint blockade immunotherapy for cancer has low response rates and combining multiple antibodies is complex and difficult, necessitating a more flexible and effective approach for combination immunotherapy.

Method used

A CRISPR-based gene silencing system using AAV-CRISPR vectors and guide RNAs targets immunosuppressive genes in immune cells and tumor cells to enhance the immune response, comprising a Cas nuclease and gRNAs specific to genes like PdL1, Galectin-9, and CD47, administered intratumorally with optional additional therapies.

Benefits of technology

Enhances anti-tumor immune response by increasing CD8+ T cell infiltration and reshaping the tumor microenvironment, showing broad antitumor activity across various cancer types and reducing metastasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095627A_ABST
    Figure CN119095627A_ABST
Patent Text Reader

Abstract

The present disclosure provides, in one aspect, a method of enhancing an immune response in a subject in need thereof. In certain embodiments, the methods comprise administering to the subject an effective amount of a gene silencing system comprising a plurality of gRNAs wherein the gene silencing system reduces expression of at least one endogenous immunosuppressive gene in a target cell, thereby enhancing the immune response. Also included are methods and compositions for enhancing an anti-tumor immune response in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 63 / 312,730, filed on February 22, 2022, which is incorporated herein by reference in its entirety.

[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0004] This invention was made with government support under CA238295, CA231112, and CA225498 awarded by the National Institutes of Health and W81XWH-20-1-0072 awarded by the U.S. Army. The government has certain rights in this invention. Background Art

[0005] Checkpoint blockade immunotherapy has transformed cancer medicine. Cancer patients who previously had few or no options can now benefit from this powerful class of drugs that can greatly improve survival.

[0006] However, single-agent checkpoint antibodies often have low response rates in patients. Combination immunotherapy involving single antibodies can improve treatment efficacy compared to single agents. However, approaches that combine more and more antibodies are exponentially more difficult because the development of each specific and effective therapeutic antibody is a difficult task in itself.

[0007] There is an urgent need for a more flexible, versatile and more effective approach for combination immunotherapy. The present disclosure addresses this need. Summary of the invention

[0008] As described herein, the present disclosure relates to methods and compositions that can be used to provide a means for combinatorial immunotherapy by administering a CRISPR-based gene silencing system that targets immunosuppressive factors expressed by both immune cells and tissues containing tumor cells.

[0009] Thus, in one aspect, the present disclosure includes a method of enhancing an immune response in a subject in need thereof, the method comprising administering to the subject an effective amount of a gene silencing system, wherein the gene silencing system reduces expression of at least one endogenous immunosuppressive gene in a target cell, thereby enhancing the immune response.

[0010] In another aspect, the present disclosure includes a method of enhancing an anti-tumor immune response in a subject in need thereof, the method comprising administering to the subject an effective amount of a gene silencing system, wherein the gene silencing system reduces the expression of at least one endogenous immunosuppressive gene in a target cell, thereby enhancing the anti-tumor immune response.

[0011] In certain embodiments, the gene silencing system is a CRISPR-based gene silencing system comprising a plurality of AAV-CRISPR vectors, wherein the plurality of AAV-CRISPR vectors comprise a Cas nuclease and a plurality of guide RNAs (gRNAs) homologous to mRNAs from a plurality of target genes associated with immunosuppression.

[0012] In certain embodiments, the gRNA sequence comprises at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-1657.

[0013] In certain embodiments, the plurality of gRNAs comprises a nucleotide sequence consisting of SEQ ID NOs: 1-1657.

[0014] In certain embodiments, the gRNA sequence comprises at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-92.

[0015] In certain embodiments, the plurality of gRNAs comprises a nucleotide sequence consisting of SEQ ID NOs: 1-92.

[0016] In certain embodiments, the target gene is selected from the group consisting of Pdl1, Galectin-9, Galectin-3, and Cd47, or any combination thereof.

[0017] In certain embodiments, the CRISPR-based gene silencing system is selected from the group consisting of a type III (Cmr / Csm) system, a type VI system, and a type II system.

[0018] In certain embodiments, the Type VI system comprises a Cas13 nuclease.

[0019] In certain embodiments, the Cas nuclease is a Cas13 nuclease.

[0020] In certain embodiments, the Cas13 nuclease is selected from the group consisting of Cas13a, Cas13b, Cas13c, and Cas13d.

[0021] In certain embodiments, the Cas13 nuclease is Cas13d.

[0022] In certain embodiments, the target cell is an immune cell.

[0023] In certain embodiments, the target cell is a T cell.

[0024] In certain embodiments, the target cell is a tumor cell.

[0025] In certain embodiments, target cells are immune cells and tumor cells.

[0026] In certain embodiments, the gene silencing system comprises an RNA interference (RNAi) system.

[0027] In certain embodiments, the RNAi system is selected from a shRNA-based system, a siRNA-based system, and a miRNA-based system.

[0028] In certain embodiments, the RNAi system targets an endogenous RNA sequence comprising the nucleic acid sequence set forth in SEQ ID NOs: 1658-1665.

[0029] In certain embodiments, the RNAi system targets a gene selected from the group consisting of CD200, CD66, Galectin 3, CD47, or any combination thereof.

[0030] In certain embodiments, the RNAi system is a shRNA system.

[0031] In certain embodiments, the shRNA system comprises at least one nucleic acid selected from the group consisting of SEQ ID NOs: 1666-1681.

[0032] In certain embodiments, the AAV-CRISPR vector is selected from the group consisting of: AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrh10, AAVrh25, Anc80L65, LK03, AAVrh18, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, Oligo001, PHP-B and Spark100.

[0033] In certain embodiments, the AAV-CRISPR vector is AAV9.

[0034] In certain embodiments, administering an effective amount of a gene silencing system comprises one, two, three, four, or more doses of treatment.

[0035] In certain embodiments, the tumor is a cancer selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, melanoma, glioma, liver cancer, colon cancer, and brain cancer.

[0036] In certain embodiments, administration of the gene silencing system results in increased CD8+ T cell infiltration into the tumor.

[0037] In certain embodiments, the gene silencing system is administered intratumorally.

[0038] In certain embodiments, it further comprises administering an additional anti-tumor therapy.

[0039] In certain embodiments, the additional anti-tumor therapy is selected from the group consisting of chemotherapy, radiation, surgery, immune checkpoint inhibitors, and immune checkpoint blocking antibodies.

[0040] In certain embodiments, the subject is a mammal.

[0041] In certain embodiments, the subject is a human.

[0042] In another aspect, the present disclosure includes a vector comprising an adeno-associated virus (AAV) genome, a U6 promoter sequence, a gRNA sequence, an EFS promoter sequence, and a Cas nuclease gene.

[0043] In certain embodiments, the gRNA sequence comprises at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-1657.

[0044] In certain embodiments, the Cas nuclease is an RNA targeting nuclease.

[0045] In certain embodiments, the Cas nuclease is a Cas13 nuclease.

[0046] In certain embodiments, the Cas13 nuclease is selected from the group consisting of Cas13a, Cas13b, Cas13c, and Cas13d.

[0047] In certain embodiments, the Cas13 nuclease is Cas13d.

[0048] In another aspect, the present disclosure includes a composition comprising a gRNA library, wherein the gRNA library comprises a plurality of gRNAs targeting a plurality of immunosuppressive genes in a cell.

[0049] In certain embodiments, the plurality of gRNAs comprises at least one gRNA selected from the group consisting of SEQ ID NOs: 1-1657.

[0050] In certain embodiments, the plurality of gRNAs comprises the nucleic acid sequences of SEQ ID NOs: 1-1657.

[0051] In certain embodiments, the plurality of gRNAs comprises the nucleic acid sequences of SEQ ID NOs: 3-92.

[0052] In certain embodiments, the plurality of gRNAs comprise nucleic acid sequences of SEQ ID NOs: 93-1657.

[0053] In certain embodiments, the gRNA library is packaged into an AAV vector. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] The following detailed description of specific embodiments of the present disclosure will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the present disclosure, exemplary embodiments are shown in the drawings. However, it should be understood that the present disclosure is not limited to the precise arrangements and means of the embodiments shown in the drawings.

[0055] Figures 1A to 1D Multiple Cas13d repression of immunosuppressive genes as combinatorial cancer immunotherapy is shown. Figure 1A : Schematic representation of the experimental design for evaluating multiple repression of immunosuppressive genes (MUCIG) as an immunotherapy. Figure 1B : Criteria for designing four different gRNA libraries targeting combinations of immunosuppressive genes. Figure 1C : Growth curve of orthotopic E0771 tumor in C57BL / 6 mice. On days 5, 9 and 14, mice were injected intratumorally with PBS (n=4), AAV-vector (n=5), AAV-MUCIG Lib1 (n=4), Lib2 (n=4), Lib3 (n=4) or Lib4 (n=5). Statistical significance was assessed by two-way ANOVA, (**p<0.01, ****p<0.0001). Figure 1D : Separated by treatment group for visibility ( Figure 1C )’s spider diagram.

[0056] Figures 2A to 2H We show that rational optimization of MUCIG resulted in AAV-PGGC, an effective four-gene combination immunotherapy. Figures 2A to 2D : Protein level characterization of immunosuppressive factors in a panel of isogenic cancer cell lines. Figure 2A :Through the surface( Figure 2A ) or intracellular ( Figure 2B ) staining was performed for FACS analysis of PGGC library targets (PD-L1, Galectin-9, Galectin-3, and CD47) in different murine cancer cell lines. Figures 2C to 2D : Detailed description of the surface expression of several immunosuppressive factors determined by FACS ( Figure 2C ) and intracellular ( Figure 2D ) Heat map of expression of . Data are presented as the percentage of total cells expressing each marker. Figure 2E : C57BL / 6 mice (n=3) were orthotopically injected with 2xe 6 E0771-GFP cells. Tumors were harvested 23 days after injection. Tumor tissues were dissociated for FACS analysis of the markers indicated in each compartment. Figure 2F : Schematic representation of the experimental design for intratumoral delivery of the four-gene AAV-PGGC cocktail. Figure 2G: Growth curve of orthotopic E0771 tumors in C57BL / 6 mice. On days 5, 9 and 14, mice were injected intratumorally with PBS (n=5), AAV-vector (n=5), AAV-MUCIGLib4 (n=5) and AAV-PGGC (n=5). Statistical significance was assessed by two-way ANOVA, (****p<0.0001). Figure 2H : Separated by treatment group for visibility ( Figure 2C )’s spider diagram.

[0057] Figures 3A to 3F AAV-PGGC therapy showed broad antitumor activity in syngeneic models of different cancer types. C57BL / 6 mice were injected subcutaneously with B16F10 melanoma cells ( Figures 3A to 3B ), CT26 colon cancer cells ( Figures 3C to 3D ) or Pan02 pancreatic cancer cells ( Figures 3E to 3F ). At the time points indicated by black arrows, mice were injected intratumorally with PBS, AAV-vector, AAV-MUCIG Lib4, or AAV-PGGC. Figure 3A : Growth curves of B16F10 tumors treated with PBS (n=5), AAV-vector (n=5), AAV-MUCIG Lib4 (n=5) and AAV-PGGC (n=5). Figure 3B : Spider plot of the growth curve in (A) separated for visibility. Figure 3C : Growth curves of CT26 tumors treated with PBS (n=5), AAV-vector (n=5), AAV-MUCIG Lib4 (n=5) and AAV-PGGC (n=5). Figure 3D : Separated for visibility ( Figure 3C ) in a spider plot of the growth curve. Figure 3E : Growth curves of Pan02 tumors treated with PBS (n=5), AAV-vector (n=5), AAV-MUCIG Lib4 (n=5) and AAV-PGGC (n=5). Figure 3F : Separated for visibility ( Figure 3E ) Spider plot of the growth curve in ). Statistical significance was assessed by two-way ANOVA, (**p<0.01, ****p<0.0001).

[0058] Figures 4A to 4I AAV-PGGC treatment was shown to reshape the immunosuppressive tumor microenvironment. Figure 4A : Schematic representation of the experimental design used to analyze the composition of tumor-infiltrating immune populations after AAV-PGGC therapy. Figure 4B: Relative abundance of several immune populations in orthotopic E0771 (upper panel) and CT26 (lower panel) tumors at the endpoint of the tumor study (35 days after tumor induction). For the E0771 model, mice were treated with PBS (n=3), AAV-vectors (n=4), or AAV-PGGC (n=4) on days 4, 9, and 14. For the CT26 model, mice were treated with PBS (n=4), AAV-vectors (n=4), or AAV-PGGC (n=4) on days 4, 9, and 14. Statistical significance was assessed by two-tailed unpaired t-test (*p<0.05, **p<0.01, ***p<0.001). Figure 4C Figure : UMAP visualization of individual tumor-infiltrating immune cells analyzed by scRNA-seq. Mice bearing orthotopic E0771 tumors were treated with PBS, AAV-vectors, or AAV-PGGC on days 4, 9, and 14. Tumors were harvested on day 29 and viable CD45 + Cells were sorted for scRNA-seq. Figure 4D : Violin plots showing the expression levels of representative marker genes in major cell clusters. Figure 4E : Relative proportion of each cell type in the treatment group. Statistical analysis between groups was performed by two-tailed Fisher's exact test. Figure 4F Figure 3: UMAP visualization of individual tumor-infiltrating immune cells analyzed by scRNA-seq. Mice bearing subcutaneous CT26 tumors were treated with PBS, AAV-vectors, or AAV-PGGC on days 4, 9, and 14. Tumors were harvested on day 29 and viable CD45 + Cells were sorted for scRNA-seq. Figure 4G : Violin plots showing the expression levels of representative marker genes in major cell clusters. Figure 4H : Relative proportion of each cell type in the treatment group. Statistical analysis between groups was performed by two-tailed Fisher's exact test. Fig. 4I : Schematic representation of AAV-PGGC therapy as a new modality for combination immunotherapy.

[0059] Figures 5A to 5D Identification of effective Cas13d gRNAs against Pdl1 and galectin-9 is shown. Figure 5A : Schematic representation of the experimental approach to identify effective gRNAs targeting Pdl1 and galectin-9. Figure 5B : Target sites of 40 Cas13d gRNAs located along the Pdl1 transcript. Figure 5C and 5D : Cas13d-gRNA to Pdl1( Figure 5C ) and galectin-9 ( Figure 5D) FACS analysis of knockdown efficacy. The gRNA with the highest knockdown efficacy is highlighted in red. Data are presented as relative mean fluorescence intensity (MFI).

[0060] Figures 6A to 6D Cas13d-mediated silencing of endogenous immunosuppressive genes in cancer cells is shown. Fig. 6A : Schematic representation of the experimental approach to identify effective Cas13d gRNAs targeting various immunosuppressive genes. Figure 6B : Knockdown efficiency of gRNA targeting different immunosuppressive genes in cancer cell lines. Data are expressed as relative mean fluorescence intensity (MFI). Figure 6C : Comparison of knockdown efficiency between WT-DR and mut-DR. Fig.6D : Comparison of Cas13d gRNA-mediated target knockdown and shRNA-mediated target knockdown. Statistical significance was assessed by two-tailed unpaired t-test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

[0061] Figure 7 Figure 3 shows sustained ectopic gene expression in tumors after intratumoral AAV injection. C57BL / 6 mice were orthotopically injected with 2x10 e 6 E0771 cells were then injected intratumorally with AAV-luciferase-GFP at the indicated time points. In vivo bioluminescence imaging was performed to visualize luciferase activity.

[0062] Figures 8A to 8B It was shown that AAV-MUCIG treatment altered the composition of immune populations in the tumor microenvironment. Figures 8A to 8B : FACS characterization of immune populations in orthotopic E0771 tumors. Mice were treated with PBS (n=4), AAV-vectors (n=5) or AAV-MUCIG Lib1 (n=4), AAV-MUCIG Lib2 (n=4), AAV-MUCIG Lib3 (n=4) and AAV-MUCIG Lib4 (n=5) on days 4, 9 and 14. Tumors were harvested on day 37 and analyzed by FACS for T cells ( Fig. 8A ) and myeloid cells ( Figure 8B ). Statistical significance was assessed by two-tailed unpaired t-test (*p<0.05, **p<0.01, ***p<0.001).

[0063] Figures 9A to 9C The common signature of downregulated genes in immune cell populations after AAV-PGGC treatment is shown. Comparison of AAV-PGGC with AAV-vectors in both CT26 and E0771 tumor models revealed CD8 + T cells ( Fig. 9A ), neutrophils ( Fig. 9B ) and macrophages ( Fig. 9C ) in the overlap of down-regulated genes.

[0064] Figures 10A to 10D In vivo studies demonstrating multiple Cas13d repression of immunosuppressive genes as a combinatorial cancer immunotherapy are shown. Fig. 10A : Growth curve of E0771 tumor in C57BL / 6 mice. 6 E0771 cells were orthotopically injected into C57BL / 6 mice. On days 5, 9, and 14, mice were intratumorally injected with PBS (n=9), AAV-MUCIG-vector (Cas13d) (n=10), AAV-MUCIG pool 1 (n=9), pool 2 (n=9), pool 3 (n=9), or pool 4 (n=10), with each dose of 2e 11 AAVs. Fig. 10B : Separated by treatment group for visibility ( Fig. 10A )’s spider diagram. Fig. 10C Figure : Growth curve of orthotopic E0771 tumors in C57BL / 6 mice. On days 5, 9, and 14, mice were injected intratumorally with AAV-vector (Cas13d) (n=10), AAV-MUCIG pool 4 (n=5), and AAV-PGGC (n=10), with 2e per dose. 11 AAVs. Fig. 10D : Separated by treatment group for visibility ( Fig. 10C )’s spider diagram.

[0065] Fig.11 The relative abundance of CD45%+ populations in orthotopic E0771 (upper panel) and subcutaneous Colon26 (lower panel) tumors at the endpoint of the tumor study (35 days after tumor induction) is shown. For the E0771 model, mice were treated intratumorally with PBS (n=3), AAV-vectors (n=4), or AAV-PGGC (n=4) on days 4, 9, and 14. For the Colon26 model, mice were treated intratumorally with PBS (n=4), AAV-vectors (n=4), or AAV-PGGC (n=4) on days 4, 9, and 14. Statistical significance was assessed by one-way ANOVA Tukey multiple comparison test, adjusted P values. (*p<0.05, **p<0.01, ***p<0.001).

[0066] Figures 12A to 12L AAV-PGGC therapy was shown to be dependent on CD8+ T cells and to suppress metastatic cancer and prolong survival. Fig. 12A: Schematic diagram of the experimental design for AAV-PGGC and antibody treatment. C57BL / 6 mice were injected orthotopically with 2xe6 E0771 cells. Mice were injected intratumorally with AAV-vectors or AAV-PGGC at the indicated time points. Tumor-bearing mice were treated intraperitoneally (IP) with 100ug of isotype control, anti-CD8 or anti-GR1 antibodies per dose at the indicated time points. Fig. 12B : Growth curves of orthotopic E0771 tumors in C57BL / 6 mice after different combinations of AAV and antibodies. Fig. 12C and 12D :from Fig. 12B Figure 2. Specific CD8+T cells isolated from AAV-PGGC treated with ( Fig. 12C ) or MDSC / neutrophils ( Fig.12D ) consumption analysis. Fig.12E : Schematic diagram of the experimental design of the dual-site tumor model. 2xe6 E0771 cells were injected orthotopically into the left fat pad of C57BL / 6 mice, and 0.2xe6 E0771 cells were injected orthotopically into the right fat pad. At the specified time points, AAV-vectors or AAV-PGGC (2e11 AAV per dose) were injected intratumorally only into the left site of the mice. Fig.12F and 12G : Primary tumor sites in C57BL / 6 mice treated with AAV-PGGC ( Fig.12F ) and distant tumor sites ( Figure 12G Statistical significance was assessed by two-way ANOVA. Fig.12H : Schematic diagram of the experimental design for the E0771 orthotopic tumor and lung distant metastasis model. C57BL / 6 mice were injected orthotopically with 2xe6 E0771-luciferase expressing cells and injected intravenously (IV) one day later with 0.2xe6 E0771-luciferase expressing cells. Mice were injected intratumorally and intravenously with AAV-vectors or AAV-PGGC (4e11 AAVs per dose) and treated intraperitoneally (IP) with 100ug of isotype or anti-Gr1 antibody per dose at the indicated time points. Fig.12I : Growth curves of primary tumors in C57BL / 6 mice after AAV-PGGC plus anti-Grl antibody treatment. Statistical significance was assessed by two-way ANOVA. Fig.12J : Measurement of lung metastasis progression by bioluminescence imaging using IVIS. Figure 12K : Survival without lung metastasis. Metastasis-free survival is defined by the luciferase signal when it first appears in the lung. In order to standardize between mice, the luciferase signal is first normalized from a minimum of 500 to a maximum of 70,000, and then the lung luciferase signal is checked for presence or absence. Survival curves are analyzed by log-rank (Mantel-Cox) test. Figure 12L: Overall survival. Survival curves were analyzed by log-rank (Mantel-Cox) test. Data points in the figure are expressed as mean ± sem. Statistical significance was assessed by two-way ANOVA or log-rank test, as shown in each figure. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Non-significant comparisons are not shown.

[0067] Fig.13 It is a histogram showing the flow cytometry analysis of the knockdown effect of Cas13d-gRNA on PDL1. The gRNA with the highest knockdown effect is highlighted in red. The data are expressed as the relative mean value (MFI) of fluorescence intensity. The gene expression level of the vector is normalized to 1.

[0068] Figures 14A to 14B A further example of Cas13d-mediated silencing of endogenous immunosuppressive genes in cancer cells is shown. Fig.14A : Schematic diagram of the experimental method to compare the knockdown efficiency of wild-type guide repeats (WT-DR) and mutants (Mut-DR). E0771 tumor cells were transduced with Cas13d-EGFP lentivirus. GFP was then sorted + Cells were transfected with WT-DR gRNA or Mut-DR gRNA plasmids. Two days after transfection, target gene expression was detected by flow cytometry analysis. Fig. 14B : Schematic diagram of the experimental method for comparing the knockdown efficiency between Cas13d gRNA and shRNA. Cas13d integrated (gRNA-Cas13-EGFP) or shRNA plasmids were transfected into Hepa1-6 or MC38 cells. Two days after transfection, target gene expression was detected by flow cytometry analysis. Cells successfully transfected with gRNA were gated by GFP+ cells.

[0069] Figures 15A to 15C Shown are tests of on-target and collateral activity of Cas13D when targeting endogenous immunosuppressive genes. Fig.15A : A graph of Cas13d collateral activity and on-target activity of the dual-GFP and mCherry reporter system. The E0711 cell line was co-transduced with three lentiviruses (Cas13d-blasticidin, GFP, and mCherry). Dual-reporter E0771 cells expressing Cas13d were selected with blasticidin and then sorted by GFP+mCherry+ double-positive cells. Dual-reporter cells were then transduced with Cas13d-guide RNA lentivirus. GFP and mCherry fluorescence signals were then measured by flow cytometry. On-target gene expression was tested by flow cytometry and qPCR. Fig. 15B: Flow cytometric analysis of E0771 dual reporter cells after transduction with different guide RNAs: NTC (non-transduced control), EV (empty vector), SCRg (scrambled guide RNA). Fig. 15C : RT-qPCR analysis of target gene expression. The gene mRNA expression level of SCRg was normalized to 1. The data points in this figure are expressed as mean ± sem. Statistical significance was assessed by one-way ANOVA Tukey multiple comparison test with adjusted P value. Multiple comparisons are summarized in the table below. *p < 0.05, **p < 0.01, ***p < 0.001.

[0070] Figures 16A to 16F AAV-PGGC therapy was shown to exhibit broad anti-tumor activity in syngeneic models of different cancer types. Fig.16A :Melanoma model. C57BL / 6 mice were injected subcutaneously with 1xe 6 At the time points indicated by black arrows, PBS (n=5), AAV-vector (n=5), AAV-MUCIG pool 4 (n=5), and AAV-PGGC (n=5) (2e per dose) were used to treat the B16F10 melanoma cells. 11 Figure 3 Growth curve of B16F10 tumors treated with AAV (Figure 3A). Fig. 16B : Spider plot of the growth curve in (A) separated for visibility. Fig. 16C : Colon cancer model. BALB / C mice were subcutaneously injected with 2xe 6 Colon26 colon cancer cells. At the time points indicated by black arrows, cells were treated with PBS (n=5), AAV-vector (n=5), AAV-MUCIG pool 4 (n=5), and AAV-PGGC (n=5) (2e per dose) 11 Growth curve of Colon26 tumors injected intratumorally with AAV (Figure 5A). Fig.16D : Separated for visibility ( Fig. 15C ) in a spider plot of the growth curve. Fig.16E : Pancreatic cancer model. C57BL / 6 mice were subcutaneously injected with 2xe 6 At the time points indicated by black arrows, cells were treated with PBS (n=5), AAV-vector (n=5), AAV-MUCIG pool 4 (n=5), and AAV-PGGC (n=5) (2e per dose). 11 Figure 3 Growth curve of Pan02 tumors treated with intratumoral AAV (Figure 3A). Fig.16F : Separated for visibility ( Fig.16E ). Data points in this figure are expressed as mean ± sem. Statistical significance was assessed by two-way ANOVA. **p < 0.01, ****p < 0.0001. Non-significant comparisons are not shown.

[0071] Fig.17 is a series of dot plots showing the gating strategy for flow cytometric staining of myeloid cells and lymphocytes. Arrows indicate the parental population that subsequent plots are gated on. CD8 + T=CD8 + CD45 + 、CD4 + =CD4 + CD45 + , Macrophages = CD11b + F4 / 80 + , dendritic cells (DC) = CD11c + MHCII + 、MDSC=CD11b + 6G + (PMN-MDSC)+CD11b + Ly6C + (M-MDSC).

[0072] Figures 18A to 18E It was shown that local treatment with AAV-PGGC modestly inhibited lung metastasis. Fig.18A : Schematic diagram of the experimental design for the E0771 orthotopic tumor and lung distant metastasis model. 2xe6 E0771-luciferase expressing cells were injected orthotopically into C57BL / 6 mice, and 0.2xe6 E0771-luciferase expressing cells were injected intravenously (IV) one day later. Then at the specified time point, AAV-vectors or AAV-PGGC (2e11 AAV per dose) were injected into the mouse tumor. Fig.18B : Growth curve of primary tumor in C57BL / 6 mice after AAV-PGGC treatment. Fig. 18C : Measurement of lung metastasis progression by bioluminescence imaging using IVIS. Representative IVIS images are shown. Fig.18D : Survival without lung metastasis. Metastasis-free survival is defined by the luciferase signal when it first appears in the lung. In order to standardize between mice, the luciferase signal is first normalized from a minimum of 100 to a maximum of 10,000, and then the lung luciferase signal is checked for presence or absence. Survival curves are analyzed by log-rank (Mantel-Cox) test. Fig.18E : Overall survival. Survival curves were analyzed by log-rank (Mantel-Cox) test. Data points in the figure are expressed as mean ± sem. Statistical significance was assessed by two-way ANOVA or log-rank test, as shown in each figure. *p < 0.05, ***p < 0.001. Non-significant comparisons are not shown. DETAILED DESCRIPTION

[0073] definition

[0074] Unless otherwise defined, all technical terms and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein may be used in the practice of testing the present disclosure, preferred materials and methods are described herein. In describing and claiming the present disclosure, the following terms will be used.

[0075] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0076] The articles "a" and "an" herein refer to one or more than one (ie, to at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.

[0077] As used herein, "about" when referring to a measurable value such as an amount, duration, etc., is meant to encompass deviations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1%.

[0078] "Allogeneic" refers to any material derived from different animals of the same species.

[0079] As used herein, the term "autologous" means any material derived from the same individual that is subsequently reintroduced into that individual.

[0080] As used herein, the term "bp" refers to base pairs.

[0081] The term "complementarity" refers to the degree of antiparallel alignment between two nucleic acid strands. Complete complementarity requires that each nucleotide is opposite its opposite nucleotide. No complementarity requires that each nucleotide is not opposite its opposite nucleotide. The degree of complementarity determines the stability of the sequences together or annealing / hybridization. In addition, various DNA repair functions as well as regulatory functions are based on base pair complementarity.

[0082] The term "CRISPR / Cas" or "Clustered Regularly Interspaced Short Palindromic Repeats" or "CRISPR" refers to a DNA locus containing short repeats of a base sequence followed by a short segment of spacer DNA from previous exposure to a virus or plasmid. Bacteria and archaea have evolved adaptive immune defenses called CRISPR / CRISPR-associated (Cas) systems that use short RNAs to direct the degradation of foreign nucleic acids. In bacteria, the CRISPR system provides acquired immunity against invading foreign DNA through RNA-guided DNA cleavage.

[0083] The term "CRISPR-Cas13d" system or "CRISPR / Cas13d" system as used herein refers to a type IV-D CRISPR / Cas system that has been modified for editing / engineering gene expression. It is generally composed of a "guide" RNA (gRNA) and a non-specific CRISPR-related nuclease (Cas13d). "Guide RNA (gRNA)" can be used interchangeably with "short guide RNA (sgRNA)" or "single guide RNA (sgRNA)" herein. gRNA is a short synthetic RNA composed of a "scaffold" sequence required for Cas13d binding and a user-defined "interval" of about 20 nucleotides or a "targeting" sequence defining a target nucleic acid. The Cas13d system differs from the CRISPR / Cas system for genome editing in that they target the nucleolytic activity of RNA (e.g., mRNA). In this way, the activity of the CRISPR-Cas13d system is to reduce gene expression by degrading mRNA transcripts rather than mutating the DNA sequence of the target gene. The RNA target of Cas13d can be changed by changing the targeting sequence present in the gRNA.

[0084] A "disease" is a health condition in an animal in which the animal is unable to maintain homeostasis and in which the animal's health continues to deteriorate if the disease is not improved. In contrast, a "disorder" in an animal is a health condition in which the animal is able to maintain homeostasis, but in which the animal's health condition is less favorable than it would be in the absence of the disorder. A disorder will not necessarily result in a further decline in the animal's health condition if left untreated.

[0085] As used herein, the term "downregulate" refers to a reduction or elimination of gene expression of one or more genes.

[0086] "Effective amount" or "therapeutically effective amount" are used interchangeably herein and refer to an amount of a compound, formulation, material or composition as described herein that is effective to achieve a specific biological result or provide a therapeutic or preventive benefit. Such results may include, but are not limited to, anti-tumor activity as determined by any suitable method in the art.

[0087] As used herein, the term "treatment" means treatment and / or prevention. A therapeutic effect is obtained by suppressing, alleviating or eradicating the disease state.

[0088] "Coding" refers to the inherent properties of the specific sequence of nucleotides in polynucleotides such as genes, cDNAs or mRNAs, which are used to serve as templates for synthesizing other polymers and macromolecules in biological processes, and the other polymers and macromolecules have defined nucleotide sequences (i.e., rRNA, tRNA and mRNA) or defined amino acid sequences and biological properties produced therefrom. Therefore, if the transcription and translation of the mRNA corresponding to a gene produce protein in a cell or other biological system, the gene encodes the protein. The coding strand (its nucleotide sequence is identical to the mRNA sequence and is generally provided in the sequence table) and the non-coding strand (used as a template for gene or cDNA transcription) can both be referred to as proteins or other products encoding the gene or cDNA.

[0089] As used herein, "endogenous" refers to any substance that originates from or is produced within an organism, cell, tissue, or system.

[0090] As used herein, the term "exogenous" refers to any substance introduced from or produced outside an organism, cell, tissue or system.

[0091] The term "expression" as used herein is defined as the transcription and / or translation of a specific nucleotide sequence driven by its promoter.

[0092] "Expression vector" refers to a vector comprising a recombinant polynucleotide comprising an expression control sequence operably linked to a nucleotide sequence to be expressed. The expression vector comprises sufficient cis-acting elements for expression; other elements for expression may be provided by a host cell or in an in vitro expression system. Expression vectors include all expression vectors known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., Sendai virus, lentivirus, retrovirus, adenovirus, and adeno-associated virus) incorporating a recombinant polynucleotide.

[0093] As used herein, "homologous" refers to the subunit sequence identity between two polymeric molecules, such as between two nucleic acid molecules (such as two DNA molecules or two RNA molecules) or between two polypeptide molecules. When a subunit position in the two molecules is occupied by the same monomer subunit; for example, if a position in each of the two DNA molecules is occupied by adenine, then they are homologous at that position. The homology between two sequences is a direct function of the number of matching or homologous positions; for example, if half of the positions in the two sequences (e.g., five positions in a polymer of ten subunits in length) are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 out of 10) are matched or homologous, the two sequences are 90% homologous.

[0094] "Identity" as used herein refers to the subunit sequence identity between two polymeric molecules, in particular between two amino acid molecules, such as between two polypeptide molecules. When two amino acid sequences have the same residue at the same position; for example, if one position in each of the two polypeptide molecules is occupied by arginine, they are identical at that position. The identity or degree to which two amino acid sequences in an alignment have the same residue at the same position is usually expressed as a percentage. The identity between two amino acid sequences is a direct function of the number of matching or identical positions; for example, if half of the positions in the two sequences (e.g., five positions in a polymer of ten amino acids in length) are identical, the two sequences are 50% identical; if 90% of the positions (e.g., 9 out of 10) are matched or identical, the two amino acid sequences are 90% identical.

[0095] As used herein, "instructional materials" include publications, records, charts, or any other medium of expression that can be used to convey the usefulness of the compositions and methods of the present disclosure. The instructional materials of the kits of the present disclosure can, for example, be fixed to a container containing the nucleic acids, peptides, and / or compositions of the present disclosure, or be transported together with a container containing the nucleic acids, peptides, and / or compositions. Alternatively, the instructional materials can be transported separately from the container in order to allow the recipient to use the instructional materials and the compounds in a cooperative manner.

[0096] "Isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide naturally present in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid or protein may exist in a substantially purified form, or may exist in a non-natural environment (e.g., a host cell).

[0097] The term "knockdown" as used herein refers to a decrease in gene expression of one or more genes.

[0098] As used herein, the term "knockout" refers to the elimination of gene expression of one or more genes.

[0099] As used herein, "lentivirus" refers to the genus of the Retroviridae family. Slow viruses are unique among retroviruses in that they are able to infect non-dividing cells; they can deliver large amounts of genetic information into the DNA of host cells, so they are one of the most effective vectors for gene delivery. HIV, SIV, and FIV are all examples of slow viruses. Vectors derived from slow viruses provide a method for achieving significant levels of gene transfer in vivo.

[0100] As used herein, the term "modified" refers to an altered state or structure of a molecule or cell of the present disclosure. Molecules can be modified in a variety of ways, including chemical modification, structural modification, and functional modification. Cells can be modified by the introduction of nucleic acids.

[0101] As used herein, the term "modulate" means to mediate a detectable increase or decrease in the level of a response in a subject compared to the level of the response in the subject in the absence of the treatment or compound, and / or compared to the level of the response in an otherwise identical but untreated subject. The term encompasses perturbing and / or influencing a natural signal or response, thereby mediating a beneficial therapeutic response in a subject (preferably a human).

[0102] As used herein, "mutation" is a change in a DNA sequence that results in an alteration of a given reference sequence (e.g., a DNA sample collected earlier from the same subject). A mutation may include a deletion and / or insertion and / or duplication and / or substitution of at least one deoxyribonucleic acid base, such as a purine (adenine and / or thymine) and / or pyrimidine (guanine and / or cytosine). A mutation may or may not result in a recognizable change in an observable characteristic (phenotype) of an organism (subject).

[0103] "Nucleic acid" means any nucleic acid, whether it is composed of deoxyribonucleosides or ribonucleosides, whether it is composed of phosphodiester bonds or modified bonds (such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethyl ester, acetamide ester, carbamate, thioether, bridged phosphoramidate, bridged methylenephosphonate, thiophosphate, methylphosphonate, dithiophosphate, bridged phosphorothioate or sulfone bond, and the combination of these bonds). The term nucleic acid also specifically includes nucleic acids composed of bases other than five kinds of alkaloids (adenine, guanine, thymine, cytosine and uracil). In the context of the present disclosure, the following abbreviations of common nucleic acid bases are used. "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.

[0104] Unless otherwise indicated, "nucleotide sequences encoding amino acid sequences" include all nucleotide sequences that are degenerate to each other and encode the same amino acid sequence. The phrase "nucleotide sequence encoding a protein or RNA" may also include introns, to the extent that a nucleotide sequence encoding a protein may contain introns in some forms.

[0105] The term "oligonucleotide" generally refers to a short polynucleotide, generally no more than about 60 nucleotides. It should be understood that when the nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e., A, U, G, C), wherein "U" replaces "T".

[0106] As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to a compound consisting of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that can constitute a protein or peptide sequence. Polypeptides include any peptide or protein that contains two or more amino acids linked to each other by peptide bonds. As used herein, the term refers to both short chains, which are also commonly referred to in the art as peptides, oligopeptides and oligomers, and long chains, which are commonly referred to in the art as proteins, which have many types. "Polypeptide" includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, etc. Polypeptides include natural peptides, recombinant peptides, synthetic peptides, or combinations thereof.

[0107] "Parenteral" administration of the immunogenic composition includes, for example, subcutaneous (sc), intravenous (iv), intramuscular (im) or intrasternal injection or infusion techniques.

[0108] As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to a compound consisting of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that can constitute a protein or peptide sequence. Polypeptides include any peptide or protein that contains two or more amino acids linked to each other by peptide bonds. As used herein, the term refers to both short chains, which are also commonly referred to in the art as peptides, oligopeptides and oligomers, and long chains, which are commonly referred to in the art as proteins, which have many types. "Polypeptide" includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, etc. Polypeptides include natural peptides, recombinant peptides, synthetic peptides, or combinations thereof.

[0109] The term "polynucleotide" as used herein is defined as a chain of nucleotides. In addition, nucleic acids are polymers of nucleotides. Therefore, nucleic acids and polynucleotides as used herein are interchangeable. It is well known to those skilled in the art that nucleic acids are polynucleotides, which can be hydrolyzed into monomeric "nucleotides". Monomeric nucleotides can be hydrolyzed into nucleosides. Polynucleotides as used herein include, but are not limited to, all nucleic acid sequences obtained by any means available in the art, including but not limited to recombinant means, i.e., cloning nucleic acid sequences from a recombinant library or a cell genome, using common cloning techniques and PCR TM etc., as well as by synthetic means. Conventional notation is used herein to describe polynucleotide sequences: the left-hand end of a single-stranded polynucleotide sequence is the 5'-end; the left-hand direction of a double-stranded polynucleotide sequence is the 5'-direction.

[0110] As used herein, a reference to a DNA or RNA nucleotide sequence refers to a polynucleotide molecule comprising the indicated bases, from left to right, in the 5' to 3' direction.

[0111] As used herein, "sample" or "biological sample" means biological material from a subject, including but not limited to organs, tissues, exosomes, blood, plasma, saliva, urine and other body fluids. A sample can be any source of material obtained from a subject.

[0112] As used herein, the term "sequencing" or "nucleotide sequencing" refers to determining the order of nucleotides (base sequences) in a nucleic acid sample (e.g., DNA or RNA). There are many technologies available, such as Sanger sequencing and high-throughput sequencing technology (also known as next-generation sequencing technology), such as Illumina's HiSeq and MiSeq platforms or the GSFLX platform provided by Roche Applied Science.

[0113] The term "subject" is intended to include living organisms (e.g., mammals) in which an immune response can be elicited. As used herein, a "subject" or "patient" can be a human or a non-human mammal. Non-human mammals include, for example, livestock and pets, such as sheep, cattle, pigs, dogs, cats, and mice. Preferably, the subject is a human.

[0114] As used herein, "substantially purified" cells are cells that are substantially free of other cell types. Substantially purified cells also refer to cells that have been separated from other cell types that are normally associated with them in their naturally occurring state. In some cases, a substantially purified cell population refers to a homogenous cell population. In other cases, the term simply refers to cells that have been separated from cells that are naturally associated with them in their native state. In some embodiments, the cells are cultured in vitro. In other embodiments, the cells are not cultured in vitro.

[0115] "Target site" or "target sequence" refers to a genomic nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule can specifically bind under conditions sufficient for binding to occur.

[0116] As used herein, the term "treatment" means treatment and / or prevention. A therapeutic effect is obtained by suppressing, alleviating or eradicating the disease state.

[0117] As used herein, the term "transfection" or "transformation" or "transduction" refers to the process of transferring or introducing exogenous nucleic acid into a host cell. A "transfected" or "transformed" or "transduced" cell is a cell that has been transfected, transformed or transduced with exogenous nucleic acid. Cells include primary subject cells and their progeny.

[0118] As used herein, the term "treating" a disease means reducing the frequency or severity of at least one sign or symptom of the disease or condition experienced by a subject.

[0119] "Vector" is a composition of matter that includes isolated nucleic acid and can be used to deliver the isolated nucleic acid to the interior of a cell. Many vectors are known in the art, including but not limited to linear polynucleotides, polynucleotides associated with ions or amphiphilic compounds, plasmids and viruses. Therefore, the term "vector" includes autonomously replicating plasmids or viruses. The term should also be interpreted as including non-plasmids and non-viral compounds that promote the transfer of nucleic acids into cells, such as polylysine compounds, liposomes, etc. Examples of viral vectors include but are not limited to Sendai virus vectors, adenovirus vectors, adeno-associated virus vectors, retroviral vectors, lentiviral vectors, etc.

[0120] As used herein, the term "T cell receptor" or "TCR" refers to a membrane protein complex that participates in activating T cells in response to the presentation of antigens. TCR is responsible for recognizing antigens bound to major histocompatibility complex molecules. TCR consists of a heterodimer of α (α) and β (β) chains, although in some cells, TCR consists of γ and δ (γ / δ) chains. TCR can exist in the form of α / β and γ / δ30, which are similar in structure but have different anatomical locations and functions. Each chain consists of two extracellular domains (variable domains and constant domains). In some embodiments, TCR can be modified on any cell including TCR, including, for example, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells and / or γδT cells.

[0121] The term "immune response" as used herein is defined as a cellular reaction to an antigen that occurs when lymphocytes recognize the antigen molecule as foreign and induce the formation of antibodies and / or activate lymphocytes to remove the antigen.

[0122] "Chimeric antigen receptor" or "CAR" refers to an engineered receptor expressed on a T cell or any other effector cell type capable of mediating cellular cytotoxicity. CAR comprises an extracellular domain having an antigen binding domain specific for a ligand or receptor. CAR optionally further comprises a transmembrane domain and a co-stimulatory signaling domain. In some embodiments, CAR comprises a hinge. In some embodiments, the antigen binding domain is specific for EGFRvIII. In some embodiments, the co-stimulatory signaling domain is a 4-1BB signaling domain. In some embodiments, CAR further comprises a CD3ζ signaling domain. CAR-T cells are T cells engineered to express CAR.

[0123] The term "co-stimulatory ligand", as used herein, includes molecules on antigen presenting cells (e.g., aAPCs, dendritic cells, B cells, etc.) that specifically bind to cognate co-stimulatory molecules on T cells, thereby providing a "second" signal (in addition to the primary signal provided by, for example, the binding of the TCR / CD3 complex to the peptide-loaded MHC molecule), mediating T cell responses, including but not limited to proliferation, activation, differentiation, etc.

[0124] "Co-stimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a co-stimulatory ligand, thereby mediating a co-stimulatory response of the T cell, such as but not limited to proliferation. Co-stimulatory molecules include but are not limited to CD28, CD27, and OX40.

[0125] Range: Throughout this disclosure, various aspects of the disclosure may be presented in the form of a range. It should be understood that the description in range format is for convenience and brevity only and should not be interpreted as a hard limitation on the scope of the disclosure. Therefore, the description of a range should be considered to have specifically disclosed all possible sub-ranges and individual numerical values ​​within the range. For example, a description of a range such as from 1 to 6 should be considered to have explicitly disclosed sub-ranges, such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc.; and individual numbers within the range, for example, 1, 2, 2.7, 3, 4, 5, 5.3 and 6. This applies regardless of the width of the range.

[0126] describe

[0127] An effective immune response is a fundamental aspect of immunotherapeutic approaches to treat a variety of diseases. However, clinically important immune responses are often limited by endogenous inhibitory mechanisms, such as the expression of so-called “immune checkpoint” or “immune checkpoint inhibitor” genes and proteins by immune cells (e.g., T cells) and surrounding tissue / tumor cells. While these complex inhibitory mechanisms can often protect self tissues from harmful, inappropriate autoimmune responses or limit the extent of typical, effective immune responses, they can also impair therapeutic immune responses. This situation particularly applies to anti-tumor immune responses, where immune tolerance mechanisms as well as other inhibitory phenomena have traditionally limited the efficacy of immunotherapeutic approaches such as cancer vaccines and T cell adoptive transfer.

[0128] The development of drugs and biomolecules (e.g., antibodies) that block and prevent the transduction of inhibitory signals by immune checkpoint proteins has achieved remarkable success in enhancing therapeutic immune responses, especially antibodies against PD-1 and CTLA-4. However, given the complexity and heterogeneity of immune signaling networks, current therapies focus on a single or a few gene or protein targets, which may result in low response rates in some patients. Similarly, while the use of two or more checkpoint blocking antibodies has demonstrated clinical effectiveness, the difficulty of combining more and more antibodies increases exponentially, as the development of each specific therapeutic antibody is itself a daunting task.

[0129] The present disclosure provides a more flexible, versatile, and effective combinatorial immunotherapy approach by administering a CRISPR-based gene silencing system that targets immunosuppressive factors expressed by both immune cells and tissues containing tumor cells.

[0130] method

[0131] The present disclosure includes methods for enhancing an immune response in vivo. One aspect of the method includes administering to a subject an effective amount of a gene silencing system, wherein the gene silencing system reduces the expression of at least one endogenous immunosuppressive gene in a target cell, thereby enhancing the immune response.

[0132] In another aspect, the present disclosure includes a method of enhancing an anti-tumor immune response in a subject in need thereof, comprising administering to the subject an effective amount of a gene silencing system, wherein the gene silencing system reduces the expression of at least one endogenous immunosuppressive gene in a target cell, thereby enhancing the anti-tumor immune response.

[0133] In certain embodiments, the gene silencing system of the present disclosure includes a CRISPR-based gene silencing system, which includes multiple AAV-CRISPR vectors. In certain embodiments, the AAV-CRISPR vector includes a Cas nuclease and a variety of guide RNAs (gRNAs) homologous to mRNA, which are transcribed by multiple target genes associated with immunosuppression. In this way, the administration of the AAV-CRISPR vector of the present disclosure leads to downregulation and / or silencing of the target gene. In certain embodiments, the AAV-CRISPR vector of the present disclosure includes at least one gRNA sequence selected from the group consisting of SEQ ID NO: 1-1657 or any combination thereof. In certain embodiments, the various gRNAs of the present disclosure include nucleic acid sequences containing SEQ ID NO: 1-1657 or any combination thereof. In certain embodiments, the various gRNAs of the present disclosure are selected from the nucleic acid sequences listed in SEQ ID NO: 1-92 or any combination thereof. In certain embodiments, the target gene is selected from the group comprising the following items: CD200, CD66, Pdl1, galectin 9, galectin 3, CD47 and any combination thereof.

[0134] In certain embodiments, the gene silencing system comprises an RNAi or RNA interference system comprising a plurality of short hairpin RNAs (shRNAs) homologous to mRNAs transcribed from a plurality of target genes associated with immunosuppression. Administration of a plurality of shRNAs to target cells results in degradation of mRNAs transcribed from target genes, thereby silencing or reducing the expression of target genes. In certain preferred embodiments, the target gene is selected from the group consisting of CD200, CD66, Pdl1, galectin 9, galectin 3, CD47, and any combination thereof.

[0135] CRISPR / Cas13d system

[0136] Type VI CRISPR-Cas systems (such as Cas13d systems) are relatively simple CRISPR systems that only require a Cas13 protein and a crispr RNA (crRNA) (which is a component of a guide RNA (gRNA)) to be active. The RNA-specific nucleolytic activity of these systems is provided by the Cas13 protein and mediated by two HEPN domains present in the protein. The guide RNA (gRNA) and the Cas protein form a complex that recognizes and cuts the target sequence, wherein the sequence of the gRNA is complementary to the target sequence. With respect to systems based on Cas13, the target sequence is an RNA containing mRNA, and the recognition of the Cas13 / gRNA complex cuts and degrades the target RNA molecule. In this way, the CRISPR system based on Cas13 can be used to silence the expression of specific genes by degrading the mRNA transcribed from these genes. Similarly, by including or applying any number of gRNAs in the Cas13 protein, the CRISPR-Cas13 system can be used to simultaneously target one or more genes. It is also expected that any RNA-targeted CRISPR system can be used in the method disclosed herein. Non-exclusive examples of RNA-targeting CRISPR systems include, but are not limited to, type III (Cmr / Csm) systems, type VI systems (including Cas13 proteins, Cas13a, Cas13b, Cas13c, and Cas13d), and type II systems.

[0137] The guide RNA is specific for the nucleic acid sequence of interest and targets the double-strand breaks and degradation regions induced by the Cas endonuclease. The target sequence of the guide RNA sequence can be within the locus of the gene or within the non-coding region of the genome or can be an RNA molecule comprising mRNA transcribed from a specific gene. In certain embodiments, the length of the guide nucleic acid sequence is at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or more nucleotides.

[0138] Guide RNA (gRNA), also known as "short guide RNA" or "sgRNA", provides targeting specificity and scaffolding / binding ability for Cas nuclease. gRNA can be a synthetic RNA composed of a targeting sequence and a scaffolding sequence derived from endogenous bacterial crRNA and tracrRNA. gRNA is used to target Cas to a specific target sequence. Guide RNA can be designed using standard tools well known in the art.

[0139] In the context of forming a CRISPR complex, a "target sequence" refers to a sequence in which the guide sequence is designed to have a certain complementarity, wherein hybridization between the target sequence and the guide sequence promotes the formation of the CRISPR complex. Provided that there is sufficient complementarity to cause hybridization and promote the formation of the CRISPR complex, complete complementarity is not necessarily required. The target sequence may comprise any polynucleotide, such as a DNA or RNA polynucleotide. In certain embodiments, the target sequence is located in the nucleus or cytoplasm of a cell. In other embodiments, the target sequence may be located in an organelle of a eukaryotic cell, such as a mitochondria or a nucleus. Typically, in the context of an endogenous CRISPR system, the formation of a CRISPR complex (comprising a guide sequence that hybridizes to a target sequence and is complexed with one or more Cas proteins) results in one or both chains being cut in or near the target sequence (e.g., within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs). As with the target sequence, it is believed that complete complementarity is not required, as long as it is sufficient to function.

[0140] In certain embodiments, one or more vectors driving the expression of one or more elements of the CRISPR gene silencing system are introduced into the target cell so that the expression of the elements of the CRISPR system guides the formation of a CRISPR complex at one or more target sites. For example, the Cas enzyme, the guide sequence connected to the tracr pairing sequence, and the tracr sequence can each be operably connected to a separate regulatory element on a separate vector. Alternatively, two or more elements expressed by the same or different regulatory elements can be combined in a single vector, wherein one or more additional vectors provide any component of the CRISPR gene silencing system not included in the first vector. The CRISPR gene silencing system elements combined in a single vector can be arranged in any suitable direction, such as an element located at 5' relative to ("upstream") of the second element or 3' relative to ("downstream") of the second element. The coding sequence 5 of an element can be located on the same or opposite chain of the coding sequence of the second element and oriented in the same or opposite direction. In certain embodiments, a single promoter drives expression of a transcript encoding a CRISPR enzyme (e.g., Cas13d) and one or more of a guide sequence, a tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g., each in a different intron, two or more in at least one intron, or all in a single intron).

[0141] In certain embodiments, the CRISPR enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more domains in addition to the CRISPR enzyme). The CRISPR enzyme fusion protein may include any additional protein sequence, and optionally a linker sequence between any two domains. Examples of protein domains that can be fused to the CRISPR enzyme include, but are not limited to, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcriptional activation activity, transcriptional repression activity, transcriptional release factor activity, histone modification activity, RNA cleavage activity, and nucleic acid binding activity. Additional domains that may form a part of a fusion protein comprising a CRISPR enzyme are described in U.S. Patent Application Publication No. US20110059502, which is incorporated herein by reference. In certain embodiments, a tagged CRISPR enzyme is used to identify the location of a target sequence.

[0142] Conventional viral and non-viral gene transfer methods can be used to introduce nucleic acids into mammalian and non-mammalian cells or target tissues. Such methods can be used to apply nucleic acids encoding components of CRISPR systems to cells in culture or host organisms. Non-viral vector delivery systems include DNA plasmids, RNA (e.g., transcripts of vectors described herein), naked nucleic acids, and nucleic acids compounded with delivery vehicles (such as liposomes). Viral vector delivery systems include DNA and RNA viruses, which have free or integrated genomes after delivery to cells (Anderson, 1992, Science 256: 808-813; and Yu et al., 1994, Gene Therapy 1: 13-26).

[0143] In certain embodiments, the vector drives the expression of the CRISPR system. The art is full of suitable vectors that can be used in the present disclosure. The vector used is suitable for replication and optionally integration in eukaryotic cells. Typical vectors contain transcription and translation terminators, initiation sequences, and promoters for regulating the expression of the desired nucleic acid sequence. The vector disclosed herein can also be used for nucleic acid standard gene delivery schemes. Methods for gene delivery are known in the art (U.S. Patent Nos. 5,399,346, 5,580,859, and 5,589,466, which are incorporated herein by reference in their entirety).

[0144] In addition, the vector can be provided to the cell in the form of a viral vector. Viral vector technology is well known in the art and is described in, for example, Sambrook et al. (4th edition, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 2012) and other virology and molecular biology manuals. The viruses that can be used as 10 kinds of vectors include but are not limited to retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, Sindbis viruses, gamma retroviruses and slow viruses. Generally, suitable vectors contain a functional origin of replication, a promoter sequence, a convenient restriction endonuclease site and one or more selective markers (e.g., WO 01 / 96584; WO 01 / 29058; and U.S. Patent No. 6,326,193) in at least one organism. In certain preferred embodiments, the vector of the present disclosure is an adeno-associated virus (AAV), which includes the CRISPR gene silencing system of the present disclosure.

[0145] AAV vector system

[0146] AAV is a relatively small non-enveloped virus with a genome of about 4kb flanked by inverted terminal repeats (ITRs). The genome contains two open reading frames, one of which provides the proteins required for replication, and the other provides the components required for building the viral capsid. Wild-type AAV is usually present in the presence of adenovirus, because adenovirus provides the accessory proteins necessary for packaging the AAV genome into virions. Therefore, the production of AAV depends on co-infection with adenovirus and depends on three key elements: ITR flanking genome, open reading frame and adeno-auxiliary genes. Because AAV has the non-pathogenicity of easily infecting human cells, it has been fully studied as a vector for gene delivery. AAV can be easily obtained, and their use as vectors for gene delivery has been described in, for example, Muzyczka, 1992; U.S. Patent No. 4,797,368 and PCT Publication WO 91 / 18088. The construction of AAV vectors is described in many publications, including Lebkowski et al., 1988; Tratschin et al., 1985; Hermonat and Muzyczka, 1984; The vectors are described in many publications, including Lebkowski et al., 1988; Tratschin et al., 1985; Hermonat and Muzyczka, 1984.

[0147] AAV-based vector systems typically separate viral AAV genes, adenovirus-derived auxiliary genes, and transgenic payloads onto two or three separate plasmids. The three-plasmid system consists of an AAV auxiliary plasmid containing rep (replication) and cap (capsid) genes, an adenovirus auxiliary plasmid containing at least the E2a gene, the E4 gene, and VA (virus-associated) RNA, and a payload plasmid containing a transgene and associated promoters and enhancers (flanked by ITR sequences). One or more auxiliary plasmids do not contain ITRs to prevent packaging of functional, infectious viral genomes. In certain embodiments, the AAV-CRISPR vector of the present disclosure comprises AAV particles containing a transgenic payload, which comprises nucleic acids encoding U6, DR.

[0148] In certain embodiments, the CRISPR-based gene silencing system of the present disclosure comprises multiple AAV-CRISPR vectors, wherein the AAV-CRISPR vector comprises a Cas nuclease (e.g., a Cas13d nuclease) and a plurality of gRNAs homologous to mRNA, the mRNA being from a plurality of target genes associated with immunosuppression. In certain embodiments, the AAV-CRISPR vector comprises an AAV particle containing a transgenic payload, the transgenic payload comprising an AAV genome, a U6 promoter sequence, a gRNA sequence, an EFS promoter sequence, and a Cas nuclease gene (e.g., a Cas13d nuclease gene).

[0149] The tissue tropism of AAV vector particles is affected by the serotype of the capsid protein, although the receptors and co-receptors that bind to the capsid protein are generally poorly understood and can be expressed by a variety of tissue types. For example, AAV2 is one of the most well-studied serotypes, with a binding affinity primarily to heparan sulfate proteoglycans (HSPGs), and therefore has a tropism for human eye, brain, lung, liver, muscle, and joint tissues. Similarly, AAV 1, 4, 5, and 6 have a binding affinity primarily to sialic acid and a tropism for neuronal tissue, while AAV 5 and 8 have a tropism for skeletal muscle cells. In this way, the serotype of the AAV capsid protein can be selected to target the payload nucleic acid of the AAV vector to a specific tissue or cell type. Changes or modifications in the capsid protein structure can also change the tissue or cell tropism and affinity of the resulting AAV vector particles.

[0150] In certain embodiments of the present disclosure, the AAV-CRISPR vector targets immune cells, including CD4+T cells, CD8+T cells, B cells, antigen presenting cells, etc. In certain embodiments, the AAV-CRISPR vector targets non-immune tissue cells, including but not limited to endothelial cells, mesenchymal cells, fibroblasts, etc., because these cells also express immunosuppressive factors that contribute to immunosuppression. In certain embodiments, the target cell is a tumor cell. The inhibition of anti-tumor immune response has been shown to be a key factor in tumor occurrence and progression, and leads to poor prognosis and patient survival, and tumor cells and tissues have been found to express a complex network of factors (including checkpoint inhibitor proteins), which contribute to the immunosuppressive properties of the tumor microenvironment (TME). In certain embodiments, the AAV-CRISPR vector of the present disclosure simultaneously targets immune cells and non-immune cells in a specific microenvironment. As a non-exclusive example, the AAV-CRISPR vectors of the present disclosure can be introduced into a tumor microenvironment, where the CRISPR-based gene silencing system of the present disclosure inhibits the expression of one or more immunosuppressive genes expressed by immune and non-immune cells (including tumor cells), with the overall effect being an improvement in the anti-tumor immune response.

[0151] It is contemplated that the AAV-CRISPR vectors of the present disclosure can be used with any naturally occurring, modified, hybrid or engineered AAV capsid protein, including but not limited to AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrh10, AAVrh25, Anc80L65, LK03, AAVrh18, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, Oligo001, PHP-B and Spark100, etc. In certain embodiments, the AAV-CRISPR vector is AAV9. A skilled person will be able to select a suitable capsid protein for use in the present disclosure based on the desired target tissue or cell type.

[0152] Composition

[0153] In certain embodiments, the present disclosure encompasses the use of "guide RNA" (gRNA), which can be used in combination with RNA-targeted CRISPR systems to regulate gene expression by targeting and degrading specific mRNA sequences.

[0154] In one aspect, the present disclosure includes a guide RNA (gRNA) library targeting multiple immunosuppressive genes in target cells. In some embodiments, the gRNA library comprises a plurality of nucleic acids comprising one or more nucleotide sequences selected from the group consisting of SEQ ID NO.1-1,657. In a further embodiment, the library further comprises at least one nucleotide sequence selected from the group consisting of SEQ ID NO.3-92. In a further embodiment, the library further comprises at least one nucleotide sequence selected from the group consisting of SEQ ID NO.93-1,657. In some embodiments, the gRNA library comprises a plurality of nucleic acids comprising the nucleotide sequence of SEQ ID NO.1-1,657. In a further embodiment, the library comprises a plurality of nucleic acids comprising the nucleotide sequence of SEQ ID NO.3-92. In a further embodiment, the library comprises a plurality of nucleic acids comprising the nucleotide sequence of SEQ ID NO.93-1,657. In certain embodiments, the library may be packaged into a vector. Any vector known to those of ordinary skill in the art may be used, including but not limited to lentiviral vectors, adenoviral vectors, and adeno-associated virus (AAV) vectors.

[0155] With respect to any of the gRNA libraries or lentiviral libraries comprising SEQ ID NOs. 1-1,657 or any combination thereof, one of ordinary skill in the art should understand that the present disclosure is interpreted as covering each individual SEQ ID NO. within the scope and all combinations thereof.

[0156] The disclosure also includes vectors, such as AAV-CRISPR vectors. The vector includes an adeno-associated virus (AAV) genome, a U6 promoter sequence, a gRNA sequence, an EFS promoter sequence, and a Cas nuclease gene. The vector may include additional components, including but not limited to LTR sequences, aT2A sequences, linker sequences, NLS sequences, and short PA sequences. In certain embodiments, the first promoter is a U6 promoter and / or the second promoter is an EFS promoter.

[0157] Any promoter known to those of ordinary skill in the art may be incorporated into any of the vectors disclosed herein. Suitable promoters and enhancer elements are known to those of skill in the art. For expression in bacterial cells, suitable promoters include, but are not limited to, lacI, lacZ, T3, T7, gpt, λP, and trc. For expression in eukaryotic cells, suitable promoters include, but are not limited to, light chain and / or heavy chain immunoglobulin gene promoters and enhancer elements; cytomegalovirus immediate early promoter; herpes simplex virus thymidine kinase promoter; early and late SV40 promoters; promoters present in long terminal repeats of retroviruses; mouse metallothionein-I promoter; and various tissue-specific promoters known in the art. Suitable reversible promoters, including reversible inducible promoters, are known in the art. Such reversible promoters can be isolated and derived from many organisms, such as eukaryotes and prokaryotes. Modification of a reversible promoter derived from a first organism (e.g., a first prokaryote and a second eukaryote, a first eukaryote and a second prokaryote, etc.) for use in a second organism is known in the art. Such reversible promoters and systems based on such reversible promoters but also comprising other control proteins include, but are not limited to, ethanol-regulated promoters (e.g., alcohol dehydrogenase I (alcA) gene promoter, promoters responsive to ethanol transactivator protein (A1cR), etc.), tetracycline-regulated promoters (e.g., promoters including Tet activator (TetActivator), TetON, TetOFF, etc.), steroid-regulated promoters (e.g., rat glucocorticoid receptor promoter system, human estrogen receptor promoter system, retinoid promoter system, etc.), The invention relates to promoters of the invention, for example, proteasome promoter systems, thyroid promoter systems, ecdysone promoter systems, mifepristone promoter systems, etc.), metal-regulated promoters (e.g., metallothionein promoter systems, etc.), promoters regulated by related pathogenesis (e.g., promoters regulated by salicylic acid, promoters regulated by ethylene, promoters regulated by benzothiadiazole, etc.), temperature-regulated promoters (e.g., heat shock-inducible promoters (e.g., HSP-70, HSP-90, soybean heat shock promoter, etc.), light-regulated promoters, synthetic inducible promoters, etc.

[0158] Other examples of suitable promoters include the immediate early cytomegalovirus (CMV) promoter sequence. The promoter sequence is a strong constitutive promoter sequence capable of driving high-level expression of any polynucleotide sequence operably connected thereto. Other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV) or human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukosis virus promoter, Epstein-Barr (Epstein-Barr) virus immediate early promoter, Rous (Rous) sarcoma virus promoter, EF-1α promoter, and human gene promoters, such as but not limited to actin promoter, myosin promoter, hemoglobin promoter and creatine kinase promoter. In addition, the present disclosure should not be limited to the use of constitutive promoters. Inducible promoters are also considered as part of the present disclosure. The use of an inducible promoter provides a molecular switch that can turn on the expression of a polynucleotide sequence operably linked thereto when such expression is desired, or can turn off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.

[0159] In certain embodiments, the vector comprises a U6 promoter and / or an EFS promoter. Certain embodiments of the present disclosure include more than one promoter per vector. One of ordinary skill in the art will appreciate that when a vector comprises more than one promoter, the promoter may comprise two or more identical promoters or two or more different promoters. For example, a vector may comprise a first promoter comprising a U6 promoter and a second promoter comprising an EFS promoter.

[0160] In addition, any of the vectors / plasmids disclosed herein may contain additional components. For example, antibiotic resistance genes / sequences. Any antibiotic resistance gene / sequence or selection marker known to those of ordinary skill in the art may be included in the vector.

[0161] The present disclosure should be construed to encompass any type of vector known to those of ordinary skill in the art. For example, the vector may comprise an adeno-associated virus, but may also comprise other viral vectors, including but not limited to adenovirus, lentivirus, retrovirus, hybrid virus vectors, or any combination thereof.

[0162] Cancer and other diseases / conditions

[0163] Certain embodiments of the present disclosure include compositions and methods for enhancing immune responses. In other aspects, the present disclosure includes compositions and methods for enhancing anti-tumor immune responses. It is expected that any disease that can be targeted by an immune response can be treated with a composition of the present disclosure that enhances such an immune response. Diseases / disorders / conditions that can be treated include, but are not limited to, autoimmune diseases, inflammation, neuroimmune disorders, and other immune system disorders.

[0164] The present disclosure includes compositions and methods for enhancing anti-tumor immune responses. The enhancement of such responses causes the patient's immune system or the cancer-specific immune cells transferred by adoptive transfer to kill tumor cells to a greater extent, thereby treating cancer. The types of cancer that can be treated include, but are not limited to, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, AIDS-related cancers, Kaposi's sarcoma, AIDS-related lymphomas, primary CNS lymphomas, anal cancer, appendix cancer (gastrointestinal carcinoid), astrocytoma, atypical teratoma / rhabdoid tumor, brain cancer, basal cell carcinoma of the skin, bile duct cancer, bladder cancer, bone cancer (including Ewing's sarcoma and osteosarcoma and malignant fibrous histiocytoma), brain tumors, breast cancer, bronchial tumors, Burkitt's lymphoma, non-Hodgkin's lymphoma, carcinoid tumors, Cancer of unknown primary, cardiac (heart) tumors, embryonal tumors, germ cell tumors, primary CNS lymphomas, cervical cancer, bile duct cancer, chordoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myeloproliferative neoplasms, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome), ductal carcinoma in situ (DCIS), endometrial cancer, ependymoma, esophageal cancer, olfactory neuroblastoma, Ewing sarcoma, extracranial germ cell tumors, eye cancer, intraocular melanoma, fallopian tube cancer, bone fibrous histiocytoma, osteosarcoma, gallbladder cancer, stomach cancer, gastrointestinal carcinoid, gastrointestinal stromal tumors (GIS T), central nervous system germ cell tumors, extracranial germ cell tumors, extragonadal germ cell tumors, ovarian germ cell tumors, testicular cancer, gestational trophoblastic disease, hairy cell leukemia, head and neck cancer, heart tumors, hepatocellular (liver) cancer, histiocytosis (Langerhans cell), Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, kidney cancer, renal cell carcinoma, Langerhans cell histiocytosis, laryngeal cancer, leukemia, lip and oral cancer, liver cancer, lung cancer (non-small cell and small cell), lymphoma, male breast cancer, malignant fibrous histiocytoma of bone and osteosarcoma, melanoma, intraocular (eye) melanoma Pigmented tumor, Merkel cell carcinoma (skin cancer), malignant mesothelioma, metastatic cancer, metastatic squamous neck carcinoma with occult primary, midline carcinoma with NUT gene alteration, oral cancer, multiple endocrine neoplasia syndrome, multiple myeloma / plasma cell neoplasms, mycosis fungoides (lymphoma), myelodysplastic syndrome, myelodysplastic / myeloproliferative neoplasms, nasal and sinus cancer, nasopharyngeal cancer, neuroblastoma, non-small cell lung cancer, oral and oropharyngeal cancer, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary tumor, plasma cell neoplasms / multiple myeloma, pleuropulmonary blastoma,Primary central nervous system (CNS) lymphoma, primary peritoneal cancer, prostate cancer, rectal cancer, recurrent cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, vascular tumors, uterine sarcoma, Sezary syndrome (lymphoma), small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, laryngeal cancer, thymoma, thymic cancer, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, cancer of unknown primary, cancer of the ureter and renal pelvis, transitional cell carcinoma, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer, Wilms' tumor, and combinations thereof.

[0165] In certain embodiments, additional treatments may be administered to the subject, such as, but not limited to, anti-tumor treatments. For example, a combination of the compositions of the present disclosure and additional treatments may be administered to the subject, such as, but not limited to, anti-tumor treatments. Examples of additional treatments include, but are not limited to, chemotherapy, radiotherapy, surgery, drugs, immune checkpoint inhibitors, immune checkpoint blocking (ICB) antibodies, immune checkpoint inhibitors that block CTLA-4 or PD1, anti-CTLA4 monoclonal antibodies, anti-PD1 monoclonal antibodies, anti-PD-L1 monoclonal antibodies, adoptive cell transfer, human recombinant cytokines, cancer vaccines, immunotherapy, targeted therapy, hormone therapy, stem cell transplantation, precision medicine, nonspecific immunotherapy (e.g., cytokines and chemokines, such as IL-2, IFNa, IFNb, IFNg), Oncolytic virus therapy, T cell therapy (e.g. adoptive transfer of TILs, CAR-T therapy), cancer vaccines (e.g. traditional DC vaccines), Ipilimumab (Yervoy), Nivolumab (Opdivo), Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Du rvalumab)(Imfinzi), anti-LAG-3, anti-TIM1, anti-TIM3, anti-CSF-R, IDO inhibitor, OX-40 agonist, GITR agonist, CD80 agonist, CD86 agonist, ICOS agonist, ICOSLG agonist, CD276 agonist, VTCN1 agonist, TNFSF14 agonist, TNFSF9 agonist, TNFSF4 agonist, CD70 agonist, CD40 agonist, LGALS9 agonist, CD80 inhibitor, CD86 inhibitor, IC OS inhibitors, ICOSLG inhibitors, CD276 inhibitors, VTCN1 inhibitors, TNFSF14 inhibitors, TNFSF9 inhibitors, TNFSF4 inhibitors, CD70 inhibitors, CD40 inhibitors, LGALS9 inhibitors, TLR9 agonists, CD20 antibodies, CD80 antibodies, TIGIT antibodies, B7-H1 antibodies, B7-H2 antibodies, B7-H3 antibodies, B7-H4 antibodies, CD28 antibodies, CD47 antibodies, anti-BTLA, anti-Galetin9, anti-IL15R, anti-GD2. In some embodiments, the monoclonal antibody is fully human, humanized or chimeric.

[0166] Introduction of nucleic acids

[0167] In certain embodiments, an expression system is used to introduce gRNA and Cas13d protein into cells of interest. Commonly used options include, but are not limited to, plasmids and viral vectors, such as adeno-associated virus (AAV) vectors or lentiviral vectors.

[0168] Methods for introducing nucleic acid into cells include physical, biological and chemical methods. Physical methods for introducing polynucleotides (such as RNA) into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, etc. RNA can be introduced into target cells using commercially available methods, including electroporation (Amaxa Nucleofector-II (Amaxa Biosystems, Cologne, Germany)), (ECM 830 (BTX) (Harvard Instruments, Boston, Mass.) or Gene Pulser II (BioRad, Denver, Colo.), Multiporator (Eppendort, Hamburg Germany). Cationic liposome-mediated transfection, lipofection, polymer encapsulation, peptide-mediated transfection or bioballistic particle delivery systems such as "gene guns" can also be used to introduce RNA into cells (see, for example, Nishikawa et al. Hum Gene Ther., 12 (8): 861-70 (2001)).

[0169] Biological methods for introducing polynucleotides of interest into host cells include the use of DNA and RNA vectors. Viral vectors, especially retroviral vectors, have become the most widely used methods for inserting genes into mammals (e.g., human cells). Other viral vectors can be derived from slow viruses, pox viruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, etc. See, e.g., U.S. Patent Nos. 5,350,674 and 5,585,362.

[0170] Chemical methods for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).

[0171] Lipids suitable for use can be obtained from commercial sources. For example, dimyristoylphosphatidylcholine ("DMPC") can be obtained from Sigma, St.Louis, MO; dihexadecyl phosphate ("DCP") can be obtained from K&K Laboratories (Plainview, NY); cholesterol ("Choi") can be obtained from Calbiochem-Behring; dimyristoylphosphatidylglycerol ("DMPG") and other lipids can be obtained from Avanti Polar Lipids, Inc. (Birmingham, AL). Lipid stock solutions in chloroform or chloroform / methanol can be stored at about -20°C. Chloroform is used as the only solvent because chloroform evaporates more easily than methanol. "Liposome" is a general term covering various monolayer and multilayer lipid vehicles formed by the generation of closed lipid bilayers or aggregates. Liposomes can be characterized as having a vesicle structure with a phospholipid bilayer membrane and an internal aqueous medium. Multilayer liposomes have multiple lipid layers separated by an aqueous medium. When phospholipids are suspended in an excess of aqueous solution, phospholipids are formed spontaneously. The lipid components rearrange themselves before forming a closed structure, and water and dissolved solutes are trapped between the lipid bilayers (Ghosh et al., 1991 Glycobiology 5: 505-10). However, compositions having structures different from normal vesicle structures in solution are also contemplated. For example, lipids may present micellar structures or exist only as heterogeneous aggregates of lipid molecules. Lipofectamine-nucleic acid complexes are also contemplated.

[0172] Regardless of the method used to introduce exogenous nucleic acid into host cells or otherwise expose cells to the inhibitors of the present disclosure, a variety of assays can be performed to confirm the presence of nucleic acid in host cells. Such assays include, for example, "molecular biology" assays well known to those skilled in the art, such as Southern and Northern blotting, RT-PCR and PCR; "biochemical" assays, such as detecting the presence or absence of specific peptides, such as by immunological means (ELISA and protein blotting) or by assays described herein to identify agents that fall within the scope of the present disclosure.

[0173] Furthermore, the nucleic acid may be introduced by any means, such as transducing cells, transfecting cells, and electroporating cells. One nucleic acid may be introduced into cells by one method, and another nucleic acid may be introduced into cells by a different method.

[0174] RNA

[0175] In certain embodiments, the nucleic acid introduced into the cell is RNA. In another embodiment, RNA is an mRNA comprising RNA or synthetic RNA transcribed in vitro. RNA is produced by in vitro transcription using a template generated using polymerase chain reaction (PCR). DNA of interest from any source can be directly converted into a template by PCR, using appropriate primers and RNA polymerase to synthesize in vitro mRNA. The source of DNA can be, for example, genomic DNA, plasmid DNA, phage DNA, cDNA, synthetic DNA sequence or any other suitable DNA source.

[0176] PCR can be used to generate templates for in vitro transcription of mRNA, which are then introduced into cells. Methods for performing PCR are well known in the art. Primers for PCR are designed to have regions that are substantially complementary to the DNA regions used as PCR templates. As used herein, "substantially complementary" refers to nucleotide sequences in which most or all of the bases in the primer sequence are complementary, or one or more bases are non-complementary or mismatched. Substantially complementary sequences can anneal or hybridize with the expected DNA target under the annealing conditions used for PCR. Primers can be designed to be substantially complementary to any part of the DNA template. For example, primers can be designed to amplify gene portions (open reading frames) that are normally transcribed in cells, including 5' and 3' UTRs. Primers can also be designed to amplify a portion of a gene encoding a specific domain of interest. In certain embodiments, primers are designed to amplify the coding region of human cDNA, including all or part of 5' and 3' UTRs. Primers that can be used for PCR are produced by synthetic methods well known in the art. "Forward primer" is a primer that contains a nucleotide region that is substantially complementary to the nucleotides on the DNA template upstream of the DNA sequence to be amplified. "Upstream" is used herein to refer to position 5 of the DNA sequence to be amplified relative to the coding strand. A "reverse primer" is a primer that contains a nucleotide region that is substantially complementary to a double-stranded DNA template downstream of the DNA sequence to be amplified. "Downstream" is used herein to refer to position 3' of the DNA sequence to be amplified relative to the coding strand.

[0177] Chemical structures that can promote the stability and / or translation efficiency of RNA can also be used. RNA preferably has 5' and 3' UTR. In certain embodiments, the length of 5' UTR is between zero and 3000 nucleotides. The length of 5' and 3' UTR sequences to be added to the coding region can be changed by different methods, including but not limited to designing PCR primers that anneal to different regions of UTR. Using this method, those of ordinary skill in the art can modify the 5' and 3' UTR lengths required for achieving optimal translation efficiency after the RNA transcribed by transfection.

[0178] The 5' and 3' UTRs can be naturally occurring endogenous 5' and 3' UTRs of the target gene. Alternatively, a non-endogenous UTR sequence can be added to the target gene by incorporating the UTR sequence into the forward and reverse primers or by any other modification of the template. The use of a non-endogenous UTR sequence for the target gene can be used to change the stability and / or translation efficiency of the RNA. For example, it is known that AU-rich elements in the 3' UTR sequence can reduce the stability of the mRNA. Therefore, the 3' UTR can be selected or designed based on the properties of the UTRs well known in the art to increase the stability of the transcribed RNA.

[0179] In certain embodiments, the 5'UTR may contain a Kozak sequence of an endogenous gene. Alternatively, when a non-endogenous 5'UTR is added to the target gene by PCR as described above, a consensus Kozak sequence can be redesigned by adding a 5'UTR sequence. The Kozak sequence can increase the translation efficiency of certain RNA transcripts, but it does not appear that all RNAs require a Kozak sequence to achieve efficient translation. The need for Kozak sequences in many mRNAs is known in the art. In other embodiments, the 5'UTR may be derived from an RNA virus whose RNA genome is stable in the cell. In other embodiments, various nucleotide analogs may be used in the 3' or 5'UTR to prevent exonuclease degradation of the mRNA.

[0180] In order to synthesize RNA from DNA template, the transcription promoter should be connected to the upstream of the sequence to be transcribed of the DNA template. When the sequence serving as RNA polymerase promoter is added to the 5' end of the forward primer, the RNA polymerase promoter is incorporated into the PCR product upstream of the open reading frame to be transcribed. In certain embodiments, the promoter is a T7 polymerase promoter, as described elsewhere herein. Other useful promoters include but are not limited to T3 and SP6 RNA polymerase promoters. The consensus nucleotide sequence of T7, T3 and SP6 promoters is known in the art.

[0181] In certain embodiments, the mRNA has both a cap at the 5' end and a 3' poly (A) tail, which determines ribosome binding, translation initiation, and stability of the mRNA in the cell. On a circular DNA template (e.g., plasmid DNA), RNA polymerase produces long concatemer products that may not be suitable for expression in eukaryotic cells. Transcription of plasmid DNA linearized at the 3'UTR end will produce normal-sized mRNA, which may not be effective in eukaryotic transfection even if polyadenylated after transcription.

[0182] On a linear DNA template, bacteriophage T7 RNA polymerase can extend the 3' end of the transcript beyond the last base of the template (Schenborn and Mierendorf, Nuc Acids Res., 13:6223-36 (1985); Nacheva and Berzal-Herranz, Eur. J. Biochem., 270:1485-65 (2003)).

[0183] The traditional method for incorporating polyA / T stretches into DNA templates is through molecular cloning. However, polyA / T sequences integrated into plasmid DNA can lead to plasmid instability, which is why plasmid DNA templates obtained from bacterial cells are often highly contaminated with deletions and other aberrations. This makes the cloning process not only laborious and time-consuming, but also often unreliable. This is why a method for constructing DNA templates with polyA / T 3' extensions without cloning is highly desired.

[0184] The poly A / T fragment of the transcribed DNA template can be generated during PCR by using a reverse primer containing a poly T tail, such as a 100T tail (which can be 50 to 5000 T in size), or by any other method after PCR, including but not limited to DNA ligation or in vitro recombination. The poly (A) tail also provides stability to the RNA and reduces its degradation. In general, the length of the poly (A) tail is positively correlated with the stability of the transcribed RNA. In certain embodiments, the poly (A) tail has 100 to 5000 adenosines.

[0185] The poly (A) tail of RNA can be further extended using poly (A) polymerase (such as E. coli poly A polymerase (E-PAP)) after in vitro transcription. In certain embodiments, the length of the poly (A) tail is increased from 100 nucleotides to 300 to 400 nucleotides, resulting in an increase in the translation efficiency of RNA by about two times. In addition, connecting different chemical groups to the 3' end can increase mRNA stability. This connection can include modified / artificial nucleotides, aptamers and other compounds. For example, poly (A) polymerase can be used to incorporate ATP analogs into the poly (A) tail. ATP analogs can further increase the stability of RNA.

[0186] The 5' cap also provides stability to the RNA molecule. In a preferred embodiment, the RNA produced by the methods disclosed herein comprises a 5' cap. The 5' cap is provided using techniques known in the art and described herein (Cougot et al., Trends in Biochem. Sci., 29: 436-444 (2001); Stepinski et al., RNA, 7: 1468-95 (2001); Elango et al., Biochim. Biophys. Res. Commun., 330: 958-966 (2005)).

[0187] The RNA produced by the method disclosed herein can also contain an internal ribosome entry site (IRES) sequence. The IRES sequence can be any virus, chromosome or artificially designed sequence, which initiates the binding of the cap-independent ribosome to the mRNA and promotes the initiation of translation. Any solute suitable for cell electroporation can be included, which can contain factors that promote cell permeability and vitality, such as sugars, peptides, lipids, proteins, antioxidants and surfactants.

[0188] In some embodiments, RNA is electroporated into cells, such as in vitro transcribed RNA.

[0189] This method also provides the ability to control expression levels over a wide range by changing, for example, the promoter or the amount of input RNA, making it possible to individually regulate expression levels. In addition, PCR-based mRNA production technology greatly facilitates the design of mRNAs with different structures and their domain combinations.

[0190] One advantage of the RNA transfection method disclosed herein is that RNA transfection is essentially instantaneous and vector-free. RNA transgenes can be delivered to lymphocytes and expressed therein after brief in vitro cell activation as a minimal expression cassette without the need for any additional viral sequences. Under these conditions, the transgene is unlikely to integrate into the host cell genome. Due to the efficiency of RNA transfection and its ability to uniformly modify an entire lymphocyte population, there is no need to clone cells.

[0191] Genetic modification of cells using in vitro transcribed RNA (IVT-RNA) uses two different strategies, both of which have been tested successively in various animal models. Cells are transfected with in vitro transcribed RNA by lipofection or electroporation. Various modifications are required to stabilize the IVT-RNA in order to achieve prolonged expression of the transferred IVT-RNA.

[0192] Some IVT vectors are known in the literature, which are used in a standardized manner as templates for in vitro transcription and have been genetically modified in such a way that stable RNA transcripts are produced. The protocols currently used in the art are based on plasmid vectors with the following structure: a 5' RNA polymerase promoter capable of RNA transcription, followed by the gene of interest flanked 3' and / or 5' by untranslated regions (UTRs), and a 3' poly(A) cassette containing 50 to 70 A nucleotides. Prior to in vitro transcription, the circular plasmid is linearized downstream of the poly(A) cassette by a type II restriction enzyme (the recognition sequence corresponds to the cleavage site). The poly(A) cassette therefore corresponds to the latter poly(A) sequence in the transcript. As a result of this process, some nucleotides remain after linearization as part of the enzyme cleavage site and extend or mask the poly(A) sequence at the 3' end. It is not yet clear whether this non-physiological overhang affects the amount of protein produced by such a construct in the cell.

[0193] RNA has several advantages over more traditional plasmid or viral methods. RNA-derived gene expression does not require transcription and can rapidly produce protein products following transfection. In addition, because RNA can only enter the cytoplasm and not the nucleus, typical transfection methods result in extremely high transfection rates. In addition, plasmid-based methods require that the promoter driving expression of the gene of interest is active in the cells being studied.

[0194] On the other hand, the RNA construct is delivered to the cell by electroporation. See, for example, US2004 / 0014645, US2005 / 0052630A1, US2005 / 0070841A1, US2004 / 0059285A1, US2004 / 0092907A1 for teaching the preparation and method of electroporating nucleic acid constructs into mammalian cells. Various parameters including the electric field strength required for electroporation of any known cell type are generally known in the relevant research literature and numerous patents and applications in the art. See, for example, U.S. Patent No. 6,678,556, U.S. Patent No. 7,171,264 and U.S. Patent No. 7,173,116. Devices for electroporation therapeutic applications are commercially available, such as the MedPulser TMDNA electroporation therapy system (Inovio / Genetronics, San Diego, Calif.), and described in patents, such as U.S. Patent No. 6,567,694; U.S. Patent No. 6,516,223, U.S. Patent No. 5,993,434, U.S. Patent No. 6,181,964, U.S. Patent No. 6,241,701 and U.S. Patent No. 6,233,482; Electroporation can also be used for in vitro cell transfection, such as described in US20070128708A1. Electroporation can also be used for in vitro delivery of nucleic acids to cells. Therefore, using any of the many available devices and electroporation systems known to those skilled in the art, nucleic acids (including expression constructs) are electroporated and administered to cells, providing an exciting new method for delivering RNA of interest to target cells.

[0195] Pharmaceutical composition

[0196] The pharmaceutical composition of the present disclosure may comprise an AAV-CRISPR vector or gene silencing system as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. A pharmaceutical composition comprising the engineered immune cells of the present disclosure is also provided.

[0197] The compositions of the present disclosure may include a buffer, such as neutral buffered saline, phosphate buffered saline, etc.; a carbohydrate, such as glucose, mannose, sucrose or dextran, mannitol; a protein; a polypeptide or an amino acid, such as glycine; an antioxidant; a chelating agent, such as EDTA or glutathione; an adjuvant (e.g., aluminum hydroxide); and a preservative. The compositions of the present disclosure are preferably formulated for intravenous administration.

[0198] The pharmaceutical composition of the present disclosure can be administered in a manner suitable for the disease to be treated (or prevented). The amount and frequency of administration will be determined by factors such as the patient's condition and the patient's disease type and severity, but the appropriate dosage can be determined by clinical trials.

[0199] The administration of the compositions of the present disclosure can be carried out in any convenient manner known to those skilled in the art. The compositions of the present disclosure can be administered to a subject by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein can be administered to a patient via artery, subcutaneous, intradermal, intratumoral, intranodal, intramedullary, intracapsular, intramuscular, by intravenous (iv) injection, parenteral or intraperitoneal. In other cases, the compositions of the present disclosure are directly injected into the inflammation site of the subject, the local disease site of the subject, lymph nodes, organs, tumors, etc.

[0200] It should be understood that the methods and compositions useful for the present disclosure are not limited to the specific formulations listed in the examples. The following examples are presented to provide a person of ordinary skill in the art with a complete disclosure and description of how to prepare and use the cells, expansion and culture methods, and treatment methods disclosed herein, and are not intended to limit the scope of the disclosure as the inventor deems.

[0201] Unless otherwise indicated, the practice disclosed herein employs conventional molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology techniques within the skill of the art. Such techniques are fully explained in the literature, such as "Molecular Cloning: A Laboratory Manual", Fourth Edition (Sambrook, 2012); "Oligonucleotide Synthesis" (Gait, 1984); "Culture of Animal Cells" (Freshney, 2010); "Methods in Enzymology" "Handbook of Experimental Immunology" (Weir, 1997); "Gene Transfer Vectors for Mammalian Cells" (Miller and Calos, 1987); "Short Protocols in Molecular Biology" (Ausubel, 2002); "Polymerase Chain Reaction: Principles, Applications and Troubleshooting", (Babar, 2011); "Current Protocols in Immunology" (Coligan, 2002). These techniques are applicable to the production of polynucleotides and polypeptides of the present disclosure, and therefore can be considered in making and practicing the present disclosure.Techniques particularly useful for specific embodiments are discussed in the following sections.

[0202] Experimental Examples

[0203] The present disclosure is now described with reference to the following examples. These examples are provided for illustrative purposes only, and the present disclosure is not limited to these examples, but encompasses all variations that are obvious as a result of the teachings provided herein.

[0204] The materials and methods used in these experiments are now described.

[0205] Cell lines. E0771 cells were from CH3. Hepa1-6, MC38, Colon26, B16F10, Pan02 were from ATCC. HEK293FT cells were purchased from Thermo Fisher Scientific for virus production. All cell lines were maintained in D10 medium (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum) at 37°C and 5% CO2.

[0206] Mice. Male and female mice between 6 and 12 weeks of age were used in this study. C57BL / 6Nr mice, 6 to 8 weeks of age, were purchased from Charles River Laboratories. Female mice were used for the breast cancer (E0771) model. Male mice were used for the B16F10 and Pan02 mouse models. BALB / C mice, 6 to 8 weeks of age, were purchased from Jackson Laboratories. All animals were housed under standard, individually ventilated, pathogen-free conditions with a 12 h:12 h or 13 h:11 h light cycle, room temperature (21° C. to 23° C.) and relative humidity of 40% to 60%.

[0207] Cas13d cancer cell line generation. To produce lentivirus, 20 μg of PXR001 plasmid (EF1a-Cas13d-2A-EGFP, addgene #109049) was co-transfected with 10 μg of pMD2.G and 15 μg of psPAX2 into HEK293FT cells in a 150 mm cell culture dish at a confluence of 80% to 90% using 135 μl of LipoD293 transfection reagent (Signage, SL100668). The viral supernatant was collected 48 hours after transfection and centrifuged at 3000 g for 15 minutes to remove cell debris. The supernatant was then concentrated from 20 ml to 2 ml using an Amicon Ultra-15 filter. The virus was aliquoted and stored at -80C. To generate Cas13d overexpressing cell lines, cancer cells were transduced with lentiviral PXR001, and positive cells expressing GFP were sorted by flow cytometry.

[0208] Transfection and flow cytometry knockdown efficacy testing. To test the knockdown efficacy of each gRNA, the gRNA was cloned into the BbsI site of the PXR003 plasmid (Cas13d gRNA cloning backbone, addgene #109053) and transiently transfected into cancer cells expressing Cas13d. For transfection experiments, 5x10 4 Cells were seeded into each well of a 48-well plate. 500 ng of gRNA plasmid was transfected into the cells with Lipofectamine 2000 at a 1:1 ratio to DNA. Flow cytometry was performed 48 hours after transfection.

[0209] Generation of AAV-MUCIG library. An AAV version plasmid expressing the U6 mutant direct repeat gRNA cloning site EFS-Cas13d (pAAV-U6-EFS-Cas13d) was cloned into the AAV backbone. All pooled gRNA libraries were synthesized as single-stranded oligonucleotides by Genescript or IDT. Oligonucleotides were amplified by PCR and Gibson cloned into pAAV-U6-EFS-Cas13d. Gibson products were purified and electroporated into Endura electrocompetent cells as described previously, with colony coverage of at least x100 represented by each sgRNA. AAV was generated by co-transfecting HEK293FT cells with the AAV-MUCIG library together with the AAV9 serotype plasmid and the helper plasmid PDF6. Briefly, HEK293FT cells were seeded in 150 cm dishes or hyper flasks 12 to 18 hours before transfection. When the cells reached 80% to 90% confluence, 6.2 μg of AAV-vector or AAV-MUCIG library, 8.7 μg of AAV9 serotype and 10.4 μg of PDF6 were transfected with 130 μl of PEI and added to the cells after incubation for 10 to 15 minutes. The collected replicates of multiple culture dishes were pooled to increase the yield. The cells were collected 72 hours after transfection. For AAV purification, chloroform (volume ratio 1:10) was added and shaken vigorously at 37°C for 1 hour. NaCl was added to a final concentration of 1 M and shaken until dissolved. The mixture was centrifuged at 20,000g for 15 minutes at 4C. The aqueous layer was transferred to a new tube, and PEG 8000 (10%, w / v) was then added and shaken until dissolved. The mixture was incubated on ice for 1 hour. The pellet was centrifuged at 20,000g for 15 minutes at 4°C. The supernatant was discarded and the pellet was resuspended in DPBS. The resuspension was treated with Benzonase and MgCl2 at 37°C for 30 minutes. Chloroform (volume ratio 1:1) was then added, shaken and centrifuged at 12,000g for 15 minutes at 4°C. The aqueous layer was separated and concentrated through an Ambion Ultra-15 tube. The concentrated solution was washed with PBS and the filtration process was repeated. AAV was then treated with DNase I at 37°C for 30 minutes. The genome copy number (GC) of AAV was determined by real-time qPCR using a custom TaqMan assay targeting the EFS promoter (Thermo Fisher Scientific).

[0210] AAV-g-MUCIG was tested in a syngeneic tumor model. 6Syngeneic orthotopic mammary tumors were established by transplanting 100 E0771 cells into the mammary fat pad of 6- to 8-week-old female C57BL / 6Nr mice. Then, 5, 9, and 14 days after transplantation, 2e of vehicle or MUCIG or PBS were added. 11 AAV particles were injected intratumorally into tumor-bearing mice. Tumor volume was measured every 3 to 4 days. For the B16F10 melanoma model, 1x10 6 B16F10 cancer cells were injected subcutaneously into the left flank of male C57BL / 6Nr mice. 2x10 of vehicle or MUCIG or PBS were added 5, 9, and 13 days after transplantation. 11 AAV particles were intratumorally administered to tumor-bearing mice. Tumor volume was measured every 2 days. For the pancreatic tumor model, 2x10 6 Pan02 cells were injected subcutaneously into the left flank of C57BL / 6Nr mice. Then, at 5, 14, and 18 days after transplantation, 2e of vehicle or MUCIG or PBS were added. 11 AAV particles were intratumorally administered to tumor-bearing mice. Tumor volume was measured every 3 to 4 days. For the colon tumor model, 2x10 6 CT26 cells were injected subcutaneously into the left flank of BALB / C mice. Then, at 5, 9, and 14 days after transplantation, 2e of vehicle or MUCIG or PBS were added. 11 AAV particles were intratumorally administered to tumor-bearing mice. Tumor volume was measured every 3 days. Tumor volume was calculated using the following formula: volume = π / 6*xyz. Two-way ANOVA was used to compare growth curves between treatment groups.

[0211] In vivo luciferase imaging. Bioluminescence imaging was performed to detect AAV-delivered gene expression. Mice were injected with luciferin (150 mg / kg) by intraperitoneal injection, and activity was quantified in live animals after 1 minute of exposure for 10 minutes. Photon flux was monitored by the PE IVIS Spectrum in vivo imaging system. Signal transduction was monitored and quantified by IVIS software.

[0212] Isolation of TIL. The tumor was minced into 1 mm pieces and then digested with 100U / ml collagenase IV and DNase I at 37°C for 60 minutes. The tumor suspension was filtered through a 100-μm cell strainer to remove bulky material. The cells were washed twice with wash buffer (PBS plus 2% FBS). 1 ml ACK lysis buffer was added to the lysed red blood cells by incubation at room temperature for 2 to 5 minutes. The suspension was then diluted with wash buffer and centrifuged at 400g for 5 minutes at 4°C. The cell pellet was resuspended with wash buffer and then passed through a 40μm cell strainer. The cells were centrifuged and washed twice with wash buffer. Finally, the cell pellet was resuspended in MACS buffer (PBS containing 0.5% BSA and 2mM EDTA). Single cell suspensions were used for flow cytometry staining and FACS sorting. TIL was labeled as Cd45 positive cells.

[0213] Flow cytometry. For TIL FACS analysis, single cell suspensions from tumors were prepared as described above. For the myeloid cell staining panel, anti-CD45-Percp-Cy5.5, anti-CD11b-FITC, anti-CD11c-PE / Dazzle, anti-F4 / 80-PE, anti-Ly6G-BV605, anti-Ly6C-APC, and anti-MHCII-PE / Cy7 were used. For the lymphocyte staining panel, anti-CD45-Percp-Cy5.5, anti-CD8-BV605, anti-CD4-PE. All flow cytometry antibodies were stained at a dilution of 1:100. LIVE / DEAD Near IR was diluted 1:1000 to distinguish live or dead cells.

[0214] For in vitro cancer cell line staining, cancer cells were incubated with trypsin and washed twice with PBS. For cell surface staining, surface antibodies were diluted 1:100 and stained in MACS buffer on ice for 15 minutes. Cells were washed twice with MACS buffer. For intracellular staining, the intracellular fixation and permeabilization buffer set (eBioscience) was used to fix and permeabilize cells. In brief, after surface marker staining, cells were resuspended in 100 μl of fixation / permeabilization working solution and incubated on ice for 15 minutes. Cells were then washed with 1× permeabilization buffer and centrifuged at 600 g for 5 minutes. The cell pellet was then resuspended in 100 μl of 1× permeabilization buffer containing 1:100 intracellular staining antibodies and incubated on ice for 15 minutes. After staining, cells were centrifuged at 600 g for 5 minutes and washed twice with staining buffer before analysis or sorting on a BD FACSAria. Data were analyzed using FlowJo software.

[0215] Immune cell analysis by scRNA-seq. E0771 or CT26 tumors were collected at the indicated time points after injection. Single cell suspensions were collected as described above. Cells were labeled with Cd45-Percp-Cy5.5 antibody and live / dead dye. FACS sorted cells were expressed in CD45 + The sorted cells were washed with PBS and the cell number and viability were assessed by trypan blue staining. 10,000 CD45 + Cells were used for scRNA-seq library preparation.

[0216] scRNA-seq data analysis. scRNA-seq analysis was performed using the Seurat v4 package in R. All cells from the three treatment groups (PBS, AAV-vector, and AAV-PGGC) were merged and integrated by tumor type (E0771 or CT26). The data were filtered to retain cells with mitochondrial counts <15% and 200 to 3500 unique expression signatures. The expression data for each cell were normalized by the total reads and log-transformed. Harmony was used to integrate datasets from the same tumor type to identify cell clusters. Each cell cluster was annotated by cell type using canonical marker genes, and lymphocyte populations were sub-clustered at higher resolution. To determine differences in cell type frequencies, 2x2 contingency tables were constructed for each cell type, comparing the AAV-vector and AAV-PGGC treatment groups. Two-tailed Fisher's exact test was performed on the contingency tables for each cell type. Differentially expressed genes were identified by comparing cells from AAV-vector versus AAV-PGGC treated groups using the default settings in Seurat, with statistical significance set at adjusted p < 0.05.

[0217] Statistical analysis. Data analysis was performed using GraphPad Prism v.9 and R 3.5. Unpaired, two-sided, unpaired t-tests were used to compare two groups unless otherwise stated. Two-way ANOVA was used to compare multiple groups in tumor growth curves with two independent variables. P < 0.05 was considered statistically significant.

[0218] Example 1: Using Cas13d to effectively knock down endogenous immunosuppressive genes

[0219] To evaluate the efficiency of Cas13d-mediated RNA knockdown, a Hepa1-6 tumor cell line stably expressing Cas13d-GFP was established. gRNA was then transfected into the cells, and FACS analysis of gene expression was performed 2 days after transfection ( Figure 5A). In order to identify effective gRNAs for Cas13d-mediated Pdl1 (Cd274) knockdown efficiency, 40 gRNAs targeting Pdl1 mRNA sequences were screened ( Figure 5B and Table 1). FACS analysis showed that 29 out of 40 gRNAs could successfully knock down Pdl1 ( Figure 5C and Fig.13 Among all gRNAs, g14 showed the best knockdown efficiency, resulting in a 56% ± 0.079% reduction in Pdl1. Similarly, 25 gRNAs targeting galectin-9 were designed and evaluated for knockdown efficiency. The results showed that transfection of g9 could successfully knock down galectin-9 by 45% ± 0.073% ( Figure 5D ).

[0220] A computational model for predicting Cas13d gRNAs was recently developed (HH Wessels et al., Nat Biotechnol 38, 722-727 (2020)). To further improve the design of Cas13d gRNAs for immune genes, this design tool was used to design 4 to 5 gRNAs for 4 different immunosuppressive genes of interest: Cd47, galectin 3, Cd66a, and Cd200 (Table 1). To assess the efficiency of gRNAs designed by these tools, an integrated vector including gRNA, Cas13d, and the selection marker EGFP was generated ( Fig. 6A ). FACS was performed to gate GFP-positive cells, and then the gRNA knockdown efficacy was analyzed by fluorescence intensity. The results showed that the designed gRNA could effectively knock down the target gene ( Figure 6B ). For all 4 target genes, at least one gRNA was identified for each target gene with a knockdown efficiency of more than 50%. For Cd66a, all 5 designed gRNAs showed strong knockdown. Therefore, these data indicate that the Cas13d gRNA design tool is predictive and reliable for the following multiple gene targeting. To achieve stronger gene repression, the knockdown efficiency of gRNA with wild-type direct repeat sequence (WT-DR) was compared with mutant DR as described above. WT-DR or Mut-DR-gRNA plasmids were transfected into E0771-Cas13d overexpressing cells ( Fig.14A ). FACS analysis showed that the use of mutant DR and Pdl1 gRNA increased the knockdown efficiency by 57% ± 0.026% compared with WT-DR ( Figure 6C). For Cd73 gRNA, an improvement of 26.4±0.031% was also observed using mut-DR. The study also compared the knockdown efficacy between Cas13d-mediated gRNA and shRNA (Table 2), indicating that for the same gene in the same cell type, Cas13d-mediated gRNA had better or similar knockdown than shRNA even with WT-DR ( Fig.6D and Fig. 14B ). These data suggest that Cas13d-gRNA-mediated knockdown is an effective approach to suppress the expression of multiple tumor-intrinsic immunosuppressive genes.

[0221] Table 1: Example 1 gRNA sequences

[0222]

[0223]

[0224]

[0225]

[0226] Table 2: shRNA sequences

[0227]

[0228]

[0229] Recently, Cas13d was reported to have collateral activity in human cells. When targeting transfected DsRed in HEK cells, the co-transfected reporter gene GFP was reported to be significantly downregulated. However, when targeting endogenous RNA, the extent of collateral activity may be affected by the abundance of the target RNA. To test how strong the collateral activity is when targeting endogenous immunosuppressive genes, a GFP and mCherry dual reporter system was generated, which will indicate the collateral activity of Cas13d ( Fig.15A ). Instead of transiently transfecting the reporter gene plasmid, an E0771 cell line stably expressing Cas13d, GFP, and mCherry proteins was established by lentiviral transduction to better mimic endogenous gene expression. According to flow cytometry results, GFP and mCherry reporters showed stable expression in all tested guide RNAs targeting immunosuppressive genes, including non-transduced control (NTC) and empty vector (EV) ( Fig. 15B Subsequent studies then tested these guide RNAs for specific gene targeting of proteins by flow cytometry ( Fig. 15B ). Although the scrambled controls caused very slight background knockdown of PDL1 or galectin-9, the on-target knockdown was still much stronger ( Fig. 15B). RT-qPCR was then performed to test gene knockdown at the RNA level. Data and statistical tests between groups showed specific targeting of all guide RNAs ( Fig. 15C ). These data suggest that the Cas13d guide RNA has specific targeting properties when targeting endogenous immunosuppressive genes.

[0230] Example 2: AAV-mediated immunosuppressive gene suppression as an immunotherapy approach

[0231] Given that Cas13d cannot completely knock down genes, the natural question is whether this degree of knockdown can produce effective immunomodulation in vivo and thus generate anti-tumor immunity. Adeno-associated virus (AAV) is one of the main vehicles for transgene delivery. To evaluate the feasibility of intratumoral delivery of Cas13d and gRNA in vivo, the study first generated an AAV vector expressing firefly luciferase and GFP (AAV-Luci-GFP). AAV-Luci-GFP was injected intratumorally into E0771 tumor-bearing mice and luciferase activity was analyzed by in vivo bioluminescence imaging ( Figure 7 ). Time course imaging showed that luciferase was continuously expressed in the tumor and, as expected, also in the liver ( Figure 7 ). These data suggest that intratumoral AAV injection can successfully deliver gene cargo into the TME.

[0232] After evaluating the feasibility of the Cas13d gRNA knockdown system, the next study sought to explore whether silencing multiple immunosuppressive genes in the TME by delivering Cas13d and gRNA via AAV could be used as a combination immunotherapy. This approach is called MUCIG (Multiple Universal Combination Immunotherapy by Gene Silencing). First, libraries of different sizes were designed for combinations of immunosuppressive genes ( Figure 1A , Figure 1B The first library was designed based on several criteria. By leveraging literature knowledge and immune genomic databases such as TISIDB, 588 tumor immunosuppressive genes and 535 tumor immunostimulatory genes were identified ( Figure 1B). To avoid adverse side effects, gene sets to be excluded were identified, including tumor suppressor genes (TSGs) and housekeeping genes. Top hits identified from the functional screen were further considered as genetic factors that allow cancer cells to evade the immune system, selecting genes that have been experimentally validated as targets for cancer immunotherapy. Next, a core set of genes that have recently been shown to be cancer-intrinsic T cell killing escape genes in at least 3 cancer models were identified. Therefore, a total of 125 genes were identified from the screening data. Using a hierarchical approach, four initial Cas13d gRNA libraries were designed for the MUCIG experiment (MUCIG-Lib1: 313 genes (Table 3), Lib2: 152 genes (Table 4); Lib3: 55 genes (Table 5); Lib4, 19 genes (Table 6))( Figure 1B ).

[0233] To facilitate the direct delivery of these libraries into tumors, an all-in-one AAV vector (AAV-U6-gRNAs-EFS-Cas13d) was designed ( Figure 1A ). Five gRNAs were designed for each target gene and four AAV-MUCIG libraries were generated accordingly. To evaluate the efficacy of these libraries, the E0771 syngeneic orthotopic tumor model of triple-negative breast cancer, known to be moderately responsive to immunotherapy, was used. C57BL / 6Nr(B6) mice bearing E0771 tumors were treated with the AAV-MUCIG libraries by intratumoral administration. All AAV-MUCIG-pool treatments resulted in a significant reduction in tumor burden compared to AAV-vector or PBS treatment ( Figure 1C , Figure 1D , Fig. 10A , Fig. 10B ). Among the four gene pools, MUCIG-Pool 4 showed a significantly better therapeutic effect than Pool 1 and Pool 3, and Pool 2 showed a slightly better therapeutic effect than Pool 1 and Pool 3, among which AAV-MUCIG-Pool 4 showed the strongest efficacy among the four ( Figure 1C , Figure 1D , Fig. 10A , Fig. 10B These data suggest that all four combinations of AAV-MUCIG treatments have therapeutic efficacy in this tumor model. Tumor-infiltrating CD8 + and CD4 + The trend of increasing T cell numbers ( Fig. 8A A trend toward decreased Treg cells after AAV-MUCIG-Lib4 treatment was also observed ( Fig. 8A Myeloid cell populations, including myeloid-derived suppressor cells (MDSCs) and macrophages, were also reduced ( Figure 8B ).

[0234] Table 3: MUCIG-Lib1 gRNA

[0235]

[0236]

[0237]

[0238]

[0239]

[0240]

[0241]

[0242]

[0243]

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250]

[0251]

[0252]

[0253]

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260]

[0261]

[0262]

[0263]

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270]

[0271]

[0272]

[0273]

[0274]

[0275]

[0276] Table 4: MUCIG-Lib2 gRNA

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283]

[0284]

[0285]

[0286]

[0287]

[0288]

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297] Table 5: MUCIG-Lib3 gRNA

[0298]

[0299]

[0300]

[0301]

[0302]

[0303]

[0304]

[0305]

[0306] Table 6: MUCIG-Lib4 gRNA

[0307]

[0308]

[0309]

[0310]

[0311] Example 3: Four-gene AAV-MUCIG composition induces effective anti-tumor immunity

[0312] While two of the AAV-MUCIG libraries had evidence of antitumor responses, it was hypothesized that further optimization of the library might improve therapeutic efficacy by reducing the proportion of therapeutically neutral or deleterious gRNAs delivered to tumors. To further refine the MUCIG-lib4 library, protein level expression of the genes targeted in MUCIG-Lib4 was assessed in a panel of isogenic cancer cell lines representing a variety of tumor types. As the interest was primarily in evaluating tumor-derived factors, genes that are primarily expressed in non-tumor cells, such as the T cell checkpoints Pdcd1, Lag3, and Havcr2, were excluded. In addition to the genes targeted in Lib4, these studies also tested other known immunosuppressive genes, such as Tgf-β. Through a comprehensive assessment of surface and intracellular expression, four genes (Pd-L1 / Cd247, Cd47, Galectin 9 / Lgals9, and Galectin 3 / Lgals3) were identified that were highly expressed at the protein level in different cancer cell lines ( Figures 2A to 2D ). The Human Cancer Gene Expression Database was also examined and confirmed that the human orthologs of these genes are expressed in a variety of human tumors, supporting their clinical relevance. Galectin-9 and galectin-3 were expressed exclusively intracellularly in all cell lines ( Figure 2B , Figure 2D ). Notably, current standard monoclonal antibodies are unable to inhibit such intracellular targets, however this can be achieved by Cas13d-mediated silencing as shown elsewhere herein (Figure 15). CD47 is highly expressed on the surface and is also expressed intracellularly ( Figure 2A , Figure 2B Surprisingly, PD-L1 was highly expressed intracellularly, even in cell lines that lacked PD-L1 surface expression ( Figure 2A , Figure 2B Since immune checkpoints are often induced during tumorigenesis, the expression of these genes was tested in the in vivo E0771 tumor model by flow cytometric analysis of these four proteins in single cells dissociated from tumor samples. The results showed that all four factors (Pd-l1, Cd47, galectin-9, and galectin-3) were expressed in both tumor and immune cells ( Figure 2E ).

[0313] A gRNA combination targeting these four genes was then designed as a rational and simplified version of MUCIG (termed PGGC). The AAV-PGGC pool was then delivered into E0771 tumor-bearing mice by intratumoral injection ( Figure 2F The results showed that treatment with AAV-PGGC (Pdl1-g14, Galectin 9-g9, Galectin 3-g2, Cd47-g2) resulted in a significant reduction in tumor growth, with efficacy levels similar to those of the AAV-Lib4 group ( Figures 2G to 2H To assess whether these effects apply more broadly to other tumor models, we evaluated the effects of sera from three representative models, including B16F10 melanoma (Figures A and B), CT26 colon cancer (Figure 5A), and CT26 colon cancer (Figure 6B). Figure 3C , Figure 3D ) and Pan02 pancreatic cancer ( Figure 3E , Figure 3F The anti-tumor effects of AAV-PGGC were similarly evaluated in 242 mouse models. In all three models, AAV-PGGC showed significant anti-tumor efficacy compared with the control group ( Figures 3A to 3F Importantly, even in models where AAV-Lib4 treatment failed to reduce tumor growth, AAV-PGGC demonstrated efficacy in all models (Figure 3).

[0314] To assess whether these effects apply more broadly to other tumor models, we performed 3 representative models with varying levels of response to immune checkpoint blockade antibody therapeutics, including B16F10 melanoma (resistant) ( Fig.16A and 16B )、Colon26 colon cancer (sensitivity) ( Fig. 16C and 16D ) and Pan02 pancreatic cancer (resistant) ( Fig.16E and 16F ) mouse model). In all three models, AAV-PGGC showed significant in vivo anti-tumor efficacy compared to the control group (Figure 16). Importantly, in the three models where AAV-pool 4 treatment failed to reduce tumor growth, AAV-PGGC still showed significant efficacy in all models (Figure 16). These data show that this four-gene formula of Cas13d / gRNA-pool (AAV-PGGC) is effective against different cancer types in animal models.

[0315] Example 4: AAV-PGGC therapy promotes T cell tumor infiltration while hindering the recruitment of immunosuppressive cells

[0316] Without wishing to be bound by theory, it is hypothesized that the therapeutic efficacy of AAV-PGGC is based on its modulatory effect on the immune composition of the TME. By FACS analysis, the study then characterized the tumor-infiltrating lymphoid and myeloid cell populations in mice treated with PBS, AAV-vectors or AAV-PGGC in two different syngeneic tumor models (E0771 and Colon26). Figure 4A and 17 In the E0771 tumor model, expression of CD45 + The control group of cells had more tumor infiltrating lymphocytes (TIL) ( Figure 4B and 11 ). These studies also found that CD8 + and CD4 + T cells increased significantly ( Figure 4B ). In addition, although there were no significant changes in macrophage or DC populations, Cd11b + Gr1 + MDSCs (a heterogeneous cell population with the ability to functionally suppress T cell responses) were significantly reduced ( Figure 4B In another tumor model, CT26, CD8 + There was a similar increase in TILs ( Figure 4B Although the CD4 + There was no change in TILs, but more tumor-infiltrating macrophages and DCs were present in AAV-PGGC-treated tumors than in controls ( Figure 4B ). The latter is essential for antigen presentation and initiation of adaptive immune responses.

[0317] To systematically investigate the effects of AAV-PGGC treatment on immune cell populations in the TME and their transcriptome, single-cell RNA sequencing (scRNA-seq) of tumor-infiltrating immune cells was performed in mice treated with PBS, AAV-vectors, or AAV-PGGCs ( Figures 4C to 4D ). Consistent with FACS analysis, scRNA-seq of the E0771 tumor model revealed significant changes in multiple immune cell populations after AAV-PGGC treatment ( Figure 4E ), including CD8 + T cells and proliferating CD8 + Similarly, in the CT26 model, more CD8 + T cells and proliferating CD8+ T cells ( Figures 4F to 4HOn the other hand, the abundance of neutrophils in the AAV-PGGC-treated group was significantly reduced compared with the PBS or vector control group ( Figure 4E ), which was also observed in the CT26 model ( Figure 4H ).

[0318] These studies subsequently identified the cell types whose abundance was most affected by AAV-PGGC, including CD8 + Differentially expressed genes in T cells, neutrophils, and macrophages. Many genes associated with key immunosuppressive functions, including Arg2, Il1b, Trem1, S100a8, S100a9, Tigit, and Cd37, were found to be downregulated in both the E0771 and CT26 models (Figure 9). Cd37 can inhibit Cd3-induced T cell proliferation and Cd8 + In T cells, the present study found that Cd37 was downregulated in the AAV-PGGC treatment group compared with the vector group ( Fig. 9A ). The T cell exhaustion marker Tigit was expressed in Cd8 of the AAV-PGGC treated group + T cells also decreased ( Fig. 9A Arg2 is associated with the immunosuppressive function of neutrophils and was downregulated in the AAV-PGGC group along with Ifitm1 and Ifitm3, two genes that play a role in suppressing interferon-mediated immunity ( Fig. 9B S100a8 and S100a9 are two factors that help recruit MDSCs to the TME, and they are found in macrophages and CD8 + Down-regulated in T cells ( Fig. 9C ). Consistent with the reduction in tumor-associated neutrophils observed after AAV-PGGC treatment, the neutrophil-recruiting chemokines Cxcl1 and Cxcl2 were significantly downregulated in neutrophils and macrophages isolated from tumors treated with AAV-PGGC. These data suggest that AAV-PGGC treatment can effectively reverse the immunosuppressive TME, promote T cell infiltration and reduce MDSC recruitment ( Fig. 4I ).

[0319] Example 5: AAV-PGGC combined with anti-GR1 therapy inhibits tumor growth and metastasis

[0320] Given that CD8 + Given the increase in T cells and the decrease in neutrophils, the next step was to test how these two cell populations affect the therapeutic efficacy of AAV-PGGC. + T cell or MDSC / neutrophil depletion was performed by in vivo injection of anti-CD8 or anti-GR1 antibodies, respectively ( Fig. 12A ). The results showed that CD8 + T cell depletion in mice partially compromised the antitumor effect of AAV-PGGC ( Fig. 12B and 12C ), indicating that AAV-PGGC therapy is partially dependent on CD8 + At the same time, the depletion of MDSCs and neutrophils by anti-GR1 combined with AAV-PGGC treatment could further reduce tumor burden when compared with AAV-PGGC or anti-GR1 antibody alone ( Fig. 12B and Fig.12D These data suggest that CD8 + T cells and MDSCs / neutrophils together play a key role in AAV-PGGC therapy, and the combination therapy of AAV-PGGC plus anti-GR1 has a synergistic effect.

[0321] Subsequent studies sought to determine whether the antitumor effects induced by local AAV-PGGC treatment could extend to distant tumor sites. A dual-site E0771 tumor model was used to evaluate the systemic antitumor effects of AAV-PGGC targeting injected and non-injected distant sites ( Fig.12E ). In this E0771 dual tumor model, different numbers of cells were injected into two mammary fat pads to simulate primary and distant tumors. AAV-PGGC was then injected only into the primary tumor site. The results showed that AAV-PGGC not only inhibited tumor growth at the injected primary site, but also inhibited tumor growth at distant sites that were not injected ( Fig.12F and 12G ). These data suggest that AAV-PGGC has systemic antitumor activity.

[0322] Without wishing to be bound by theory, it is hypothesized that AAV-PGGC may have a therapeutic effect on metastatic cancers of visceral organs. To investigate this possibility, a tumor model was used that included injection of E0771 cells into fat pads to form an orthotopic tumor burden, and intravenous injection of luciferase-expressing E0771 to simulate lung metastatic tumor burden ( Fig.18A ). Tumor-bearing mice were treated with AAV-PGGC by intratumoral injection, and primary tumor volume was measured to understand primary tumor burden, and bioluminescent signal was measured to understand lung metastasis burden. Mice treated with AAV-PGGC had significantly reduced primary tumor growth ( Fig.18B Importantly, AAV-PGGC also significantly prolonged lung metastasis-free survival compared with the Cas13d-vector control group and had a numerical effect on overall survival ( Figures 18C to 18E These data suggest that local treatment with AAV-PGGC has a moderate therapeutic effect on metastatic cancers in visceral organs.

[0323] Since the combination of AAV-PGGC and anti-GR1 antibody has synergistic antitumor activity, subsequent studies explored whether the combination therapy could have a stronger effect on metastasis. Direct injection of the primary tumor and intravenous injection were again used to simulate lung metastasis ( Fig.12H ). Since local injection of AAV-PGGC alone has limited effect on lung metastatic tumors, in order to better target metastatic tumors, AAV-PGGC was injected intratumorally and intravenously, and anti-GR1 was given by intraperitoneal (ip) injection. + Antibody therapy ( Fig.12H Although anti-GR1 alone had little effect, significant tumor inhibition was observed with AAV-PGGC alone or with AAV-PGGC plus anti-GR1 combination therapy ( Fig.12I In this E0771 metastatic tumor model, the AAV-PGGC plus anti-GR1 combination showed the strongest therapeutic effect against both primary tumors and metastatic disease among all treatment groups ( Figures 12I to 12L The effect of treatment on metastatic disease is assessed by metastatic tumor burden ( Fig.12J ), metastasis-free survival ( Figure 12K ) and overall survival ( Figure 12L These data suggest that AAV-PGGC combined with anti-GR1 antibody therapy has significant efficacy against systemic disease with visceral organ metastasis in a syngeneic orthotopic tumor model.

[0324] Example 6:

[0325] TME is rich in immunosuppressive factors derived from tumor cells, tumor-associated fibroblasts or infiltrating immunosuppressive cells. The immunosuppressive factors produced by immunosuppressive cells can suppress effective anti-tumor immunity through their immune checkpoint function, and can also attract and recruit immature immune cells and induce them to differentiate into immunosuppressive cells, such as MDSC, M2 macrophages or regulatory T cells (Treg). They can also affect T cells to enter the tumor core or inhibit T cell activation and proliferation. Tumor immunosuppressive factors are the main targets of therapeutic intervention because they enable tumor cells to escape the elimination of the immune system. Many preclinical studies have shown that in certain embodiments, the neutralization of immunosuppressive factors can reverse immunosuppressive TME and promote anti-tumor immunity.

[0326] Various strategies have been developed to suppress such genes or their activities, including siRNA, antisense oligonucleotides, antagonistic antibodies and small molecule inhibitors. However, the efficacy of monotherapy for immunosuppressive factors is limited to a small number of patients, prompting current efforts to explore effective combination immunotherapy. In certain embodiments, cancer gene therapy, such as local tumor overexpression of OX40L or other combined cytokines, has the potential to promote tumor regression. However, since the payload of transgenic overexpression is usually large, it is difficult to use a large number of transgenics expressing immunostimulatory factors as a combination therapy. Here, the research disclosed in this disclosure adopts the opposite approach to directly suppress multiple immunosuppressive genes simultaneously in the TME. The present disclosure utilizes the modularity of the CRISPR / Cas13d system to design a variety of combination immunotherapies, demonstrating the anti-tumor efficacy of several different libraries of different complexity. Since multiple gRNAs are simple, gRNA libraries targeting a large number of immunosuppressive genes can be easily generated and pooled.

[0327] Since the relative abundance of each gRNA affects its silencing efficiency, optimizing the library size is critical for MUCIG therapy. Therefore, the studies disclosed in this article rationally improved the library composition and tested five different library compositions at different scales. These studies showed that a simple AAV-PGGC combination therapy targeting four immune checkpoints (PD-L1, CD47, galectin 3, and galectin 9) had significant anti-tumor activity in several different tumor models, including breast cancer (E0771), melanoma (B16F10), pancreatic cancer (Pan02), and colon cancer (CT26). These results indicate that the concept of MUCIG is not limited to a single tumor type and may have broad applicability. In order to understand the mechanism of action behind the anti-tumor efficacy, the studies disclosed in this article studied the changes in the TME after AAV-PGGC treatment by FACS and scRNA-seq. The results showed that AAV-PGGC therapy enhanced CD8 + T cell infiltration and reduced MDSC abundance. At the transcriptional level, consistent downregulation of multiple immunosuppressive genes was observed in two different cancer models, as well as consistent reductions in neutrophil chemokines Cxcl1 and Cxcl2. These data suggest that AAV-PGGC therapy can attenuate the immunosuppressive TME, thereby enhancing antitumor immune responses.

[0328] The main challenges of tumor gene therapy include targeting specificity and gene delivery efficiency. Cas13d binds and cuts single-stranded RNA, thus avoiding safety issues caused by accidental DNA damage caused by Cas9 or Cas12a. In addition, Cas13d is more compact than Cas9, Cas12a and many other Cas13 family members, which provides a key advantage for viral vector delivery. Here, AAV is used to deliver Cas13d-gRNA payloads into tumors because AAV can effectively deliver exogenous genetic material in vivo with minimal toxicity. In fact, sustained exogenous gene expression was observed within two weeks after the last intratumoral injection of AAV. Although the diversity of immunosuppressive pathways across different tumors poses an important challenge to off-the-shelf use, the MUCIG approach has the versatility to target almost any reasonable gene combination using CRISPR-Cas13d and gRNA pools, providing greater flexibility and modularity compared to traditional antagonistic antibodies or small molecules. By further customizing the mixture of immunosuppressive factors targeted by MUCIG, or by utilizing more specific delivery vehicles, the therapeutic window can be optimized to minimize off-tumor toxicity while maintaining anti-tumor efficacy.

[0329] In conclusion, the studies presented here provide a demonstration of MUCIG, a versatile strategy for combinatorial cancer immunotherapy by multiply targeting immunosuppressive gene panels. By simultaneously uncovering multiple aspects of the immunosuppressive TME, MUCIG is able to drive tailored antitumor immune responses.

[0330] Examples of Examples

[0331] The following examples are provided and their numbering should not be construed as designating a level of importance.

[0332] Example 1. A method of enhancing an immune response in a subject in need thereof, the method comprising administering to the subject an effective amount of a gene silencing system, wherein the gene silencing system reduces the expression of at least one endogenous immunosuppressive gene in target cells, thereby enhancing the immune response.

[0333] Example 2. A method for enhancing an anti-tumor immune response in a subject in need thereof, the method comprising administering to the subject an effective amount of a gene silencing system, wherein the gene silencing system reduces the expression of at least one endogenous immunosuppressive gene in target cells, thereby enhancing the anti-tumor immune response.

[0334] Embodiment 3. A method according to any one of embodiments 1 to 2, wherein the gene silencing system is a CRISPR-based gene silencing system, which comprises multiple AAV-CRISPR vectors, wherein the multiple AAV-CRISPR vectors comprise Cas nucleases and multiple guide RNAs (gRNAs) homologous to mRNAs from multiple target genes associated with immunosuppression.

[0335] Embodiment 4. A method according to embodiment 3, wherein the gRNA sequence comprises at least one nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-1657.

[0336] Embodiment 5. The method according to embodiment 3, wherein the multiple gRNAs comprise a nucleotide sequence consisting of SEQ ID NO: 1-1657.

[0337] Embodiment 6. A method according to embodiment 3, wherein the gRNA sequence comprises at least one nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-92.

[0338] Embodiment 7. The method according to embodiment 3, wherein the multiple gRNAs comprise a nucleotide sequence consisting of SEQ ID NO: 1-92.

[0339] Embodiment 8. The method according to embodiment 3, wherein the target gene is selected from the group consisting of: Pdl1, Galectin-9, Galectin-3 and Cd47 or any combination thereof.

[0340] Embodiment 9. The method according to embodiment 3, wherein the CRISPR-based gene silencing system is selected from the group consisting of a type III (Cmr / Csm) system, a type VI system, and a type II system.

[0341] Embodiment 10. The method according to embodiment 9, wherein the type VI system comprises a Cas13 nuclease.

[0342] Embodiment 11. The method according to embodiment 3, wherein the Cas nuclease is Cas13 nuclease.

[0343] Embodiment 12. The method according to embodiment 11, wherein the Cas13 nuclease is selected from the group consisting of Cas13a, Cas13b, Cas13c and Cas13d.

[0344] Embodiment 13. The method according to embodiment 11, wherein the Cas13 nuclease is Cas13d.

[0345] Embodiment 14. The method according to any one of embodiments 1 to 2, wherein the target cell is an immune cell.

[0346] Embodiment 15. The method according to any one of embodiments 1 to 2, wherein the target cell is a T cell.

[0347] Embodiment 16. The method according to embodiment 2, wherein the target cell is a tumor cell.

[0348] Embodiment 17. The method according to embodiment 2, wherein the target cells are immune cells and tumor cells.

[0349] Embodiment 18. The method according to any one of embodiments 1 to 2, wherein the gene silencing system comprises an RNA interference (RNAi) system.

[0350] Embodiment 19. The method according to embodiment 18, wherein the RNAi system is selected from the group consisting of a shRNA-based system, a siRNA-based system, and a miRNA-based system.

[0351] Embodiment 20. The method according to embodiment 18, wherein the RNAi system targets an endogenous RNA sequence comprising a nucleic acid sequence listed in SEQ ID NO: 1658-1665.

[0352] Embodiment 21. The method according to embodiment 18, wherein the RNAi system targets a gene selected from the group consisting of: CD200, CD66, Galectin 3, CD47 or any combination thereof.

[0353] Embodiment 22. The method according to embodiment 18, wherein the RNAi system is a shRNA system.

[0354] Embodiment 23. The method of embodiment 22, wherein the shRNA system comprises at least one nucleic acid selected from the group consisting of SEQ ID NOs: 1666-1681.

[0355] Embodiment 24. A method according to embodiment 3, wherein the AAV-CRISPR vector is selected from the group consisting of: AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrh10, AAVrh25, Anc80L65, LK03, AAVrh18, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, Oligo001, PHP-B and Spark100.

[0356] Embodiment 25. A method according to embodiment 3, wherein the AAV-CRISPR vector is AAV9.

[0357] Embodiment 26. The method of any one of embodiments 1 to 2, wherein administering said effective amount of said gene silencing system comprises one, two, three, four or more doses of treatment.

[0358] Embodiment 27. The method according to embodiment 2, wherein the tumor is a cancer selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, melanoma, glioma, liver cancer, colon cancer and brain cancer.

[0359] Embodiment 28. The method of embodiment 2, wherein administration of the gene silencing system results in increased CD8+ T cell infiltration into the tumor.

[0360] Embodiment 29. The method according to embodiment 2, wherein the gene silencing system is administered intratumorally.

[0361] Embodiment 30. The method of embodiment 2, further comprising administering an additional anti-tumor therapy.

[0362] Embodiment 31. The method according to embodiment 30, wherein the additional anti-tumor treatment is selected from the group consisting of chemotherapy, radiation, surgery, immune checkpoint inhibitors and immune checkpoint blocking antibodies.

[0363] Embodiment 32. The method of any one of Embodiments 1 to 2, wherein the subject is a mammal.

[0364] Embodiment 33. A method according to any one of Embodiments 1 to 2, wherein the subject is a human.

[0365] Embodiment 34. A vector comprising an adeno-associated virus (AAV) genome, a U6 promoter sequence, a gRNA sequence, an EFS promoter sequence and a Cas nuclease gene.

[0366] Embodiment 35. A vector according to embodiment 34, wherein the gRNA sequence comprises at least one nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-1657.

[0367] Embodiment 36. A vector according to embodiment 34, wherein the Cas nuclease is an RNA targeting nuclease.

[0368] Embodiment 37. A vector according to embodiment 34, wherein the Cas nuclease is Cas13 nuclease.

[0369] Embodiment 38. A vector according to embodiment 37, wherein the Cas13 nuclease is selected from the group consisting of Cas13a, Cas13b, Cas13c and Cas13d.

[0370] Embodiment 39. A vector according to embodiment 37, wherein the Cas13 nuclease is Cas13d.

[0371] Embodiment 40. A composition comprising a gRNA library, wherein the gRNA library comprises a plurality of gRNAs targeting a plurality of immunosuppressive genes in a cell.

[0372] Embodiment 41. A composition according to embodiment 40, wherein the plurality of gRNAs comprises at least one gRNA selected from the group consisting of SEQ ID NO: 1-1657.

[0373] Embodiment 42. A composition according to embodiment 40, wherein the plurality of gRNAs comprise nucleic acid sequences of SEQ ID NOs: 1-1657.

[0374] Embodiment 43. A composition according to embodiment 40, wherein the multiple gRNAs comprise nucleic acid sequences of SEQ ID NO: 3-92.

[0375] Embodiment 44. A composition according to embodiment 40, wherein the plurality of gRNAs comprise nucleic acid sequences of SEQ ID NOs: 93-1657.

[0376] Embodiment 45. A composition according to embodiment 40, wherein the gRNA library is packaged into an AAV vector.

[0377] Other embodiments

[0378] The detailed description of a list of elements in any definition of a variable herein includes definitions of the variable as any single element or combination (or subcombination) of the listed elements. The detailed description of an embodiment herein includes the embodiment as any single embodiment or combination with any other embodiment or part thereof.

[0379] The disclosure of each patent, patent application and publication cited herein is incorporated herein by reference in its entirety. Although the present disclosure has been disclosed with reference to specific embodiments, it is apparent that other technical personnel in the art can design other embodiments and variations of the present disclosure without departing from the true spirit and scope of the present disclosure. The appended claims are intended to be interpreted as including all such embodiments and equivalent variations.

Claims

1. A method of enhancing an immune response in a subject in need thereof, The method comprises administering to the subject an effective amount of a gene silencing system, wherein the gene silencing system reduces the expression of at least one endogenous immunosuppressive gene in the target cells of the subject, Thereby enhancing the immune response in the subject.

2. A method of enhancing an anti-tumor immune response in a subject in need thereof, The method comprises administering to the subject having a tumor an effective amount of a gene silencing system, wherein the gene silencing system reduces the expression of at least one endogenous immunosuppressive gene in the target cells of the subject, Thereby enhancing the anti-tumor immune response in the subject.

3. The method of any one of claims 1 to 2, wherein the gene silencing system is a CRISPR-based gene silencing system comprising a plurality of AAV-CRISPR vectors, wherein the plurality of AAV-CRISPR vectors comprise Cas nucleases and a plurality of guide RNAs (gRNAs) homologous to mRNAs from a plurality of target genes associated with immunosuppression.

4. The method of claim 3, wherein the gRNA sequence comprises at least one nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-1657.

5. The method of claim 3, wherein the plurality of gRNAs comprise nucleotide sequences of SEQ ID NOs: 1-1657.

6. The method of claim 3, wherein the gRNA sequence comprises at least one nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-92.

7. The method of claim 3, wherein the plurality of gRNAs comprise nucleotide sequences of SEQ ID NOs: 1-92.

8. The method according to claim 3, wherein the target gene is selected from the group consisting of Pdl1, Galectin-9, Galectin-3 and Cd47 or any combination thereof.

9. The method of claim 3, wherein the CRISPR-based gene silencing system is selected from the group consisting of a type III (Cmr / Csm) system, a type VI system, and a type II system.

10. The method of claim 9, wherein the Type VI system comprises a Cas13 nuclease.

11. The method of claim 3, wherein the Cas nuclease is a Cas13 nuclease.

12. The method of claim 11, wherein the Cas13 nuclease is selected from the group consisting of Cas13a, Cas13b, Cas13c and Cas13d.

13. The method of claim 11, wherein the Cas13 nuclease is Cas13d.

14. The method according to any one of claims 1 to 2, wherein the target cell is an immune cell.

15. The method according to any one of claims 1 to 2, wherein the target cell is a T cell.

16. The method of claim 2, wherein the target cell is a tumor cell.

17. The method of claim 2, wherein the target cells are immune cells and tumor cells.

18. The method according to any one of claims 1 to 2, wherein the gene silencing system comprises an RNA interference (RNAi) system.

19. The method of claim 18, wherein the RNAi system is selected from the group consisting of a shRNA-based system, a siRNA-based system, and a miRNA-based system.

20. The method of claim 18, wherein the RNAi system targets an endogenous RNA sequence comprising the nucleic acid sequence set forth in SEQ ID NOs: 1658-1665.

21. The method of claim 18, wherein the RNAi system targets a gene selected from the group consisting of CD200, CD66, Galectin 3, CD47, or any combination thereof.

22. The method of claim 18, wherein the RNAi system is a shRNA system.

23. The method of claim 22, wherein the shRNA system comprises at least one nucleic acid selected from the group consisting of SEQ ID NOs: 1666-1681.

24. The method of claim 3, wherein the AAV-CRISPR vector is selected from the group consisting of AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrh10, AAVrh25, Anc80L65, LK03, AAVrh18, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, Oligo001, PHP-B, and Spark100.

25. The method of claim 3, wherein the AAV-CRISPR vector is AAV9.

26. The method of any one of claims 1 to 2, wherein administering the effective amount of the gene silencing system comprises one, two, three, four, or multiple doses of treatment.

27. The method of claim 2, wherein the tumor is a cancer selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, melanoma, glioma, liver cancer, colon cancer, and brain cancer.

28. The method of claim 2, wherein administration of the gene silencing system results in increased CD8+ T cell infiltration into the tumor.

29. The method of claim 2, wherein the gene silencing system is administered intratumorally.

30. The method of claim 2, further comprising administering to the subject an additional anti-tumor therapy.

31. The method of claim 30, wherein the additional anti-tumor therapy is selected from the group consisting of chemotherapy, radiation, surgery, immune checkpoint inhibitors, and immune checkpoint blocking antibodies.

32. The method of any one of claims 1 to 2, wherein the subject is a mammal.

33. The method of any one of claims 1 to 2, wherein the subject is a human.

34. A vector comprising an adeno-associated virus (AAV) genome, a U6 promoter sequence, a gRNA sequence, an EFS promoter sequence and a Cas nuclease gene.

35. The vector of claim 34, wherein the gRNA sequence comprises at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-1657.

36. The vector of claim 34, wherein the Cas nuclease is an RNA targeting nuclease.

37. The vector of claim 34, wherein the Cas nuclease is a Cas13 nuclease.

38. The vector of claim 37, wherein the Cas13 nuclease is selected from the group consisting of Cas13a, Cas13b, Cas13c and Cas13d.

39. The vector of claim 37, wherein the Cas13 nuclease is Cas13d.

40. A composition comprising a gRNA library, wherein the gRNA library comprises a plurality of gRNAs targeting a plurality of immunosuppressive genes in a cell.

41. The composition of claim 40, wherein the plurality of gRNAs comprises at least one gRNA selected from the group consisting of SEQ ID NOs: 1-1657.

42. The composition of claim 40, wherein the plurality of gRNAs comprise nucleic acid sequences of SEQ ID NOs: 1-1657.

43. A composition according to claim 40, wherein the multiple gRNAs comprise nucleic acid sequences of SEQ ID NOs: 3-92.

44. A composition according to claim 40, wherein the multiple gRNAs comprise nucleic acid sequences of SEQ ID NOs: 93-1657.

45. The composition of claim 40, wherein the gRNA library is packaged into an AAV vector.